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Abstract 
 Fatigue is a distressing, complex, and multidimensional sensation, that is common in 
individuals with chronic obstructive pulmonary disease (COPD), and impacts negatively on their 
functioning and quality of life. Limited research has been conducted to examine how various 
factors may influence the different dimensions of subjective fatigue experienced in these 
individuals. Four dimensions of subjective fatigue including: emotional, behavioural, cognitive, 
and physical, were examined in a convenience sample of 42 participants with COPD who 
attended an outpatient pulmonary rehabilitation program. The primary purpose of this feasibility 
study was to determine the proportion of individuals experiencing the four dimensions of fatigue, 
and to examine the relationships between these dimensions of fatigue and various influencing 
factors (dyspnea, depression, anxiety, sleep quality, activity limitation, heart rate, and oxygen 
saturation). The secondary purpose was to compare the four dimensions of fatigue by sex, 
supplemental oxygen use, smoking status, and severity of dyspnea, and to examine the 
relationships between the four dimensions of fatigue and age, the number of co-morbidities, and 
the amount of pulmonary rehabilitation received. Self-report questionnaires were used to 
measure fatigue (Multidimensional Fatigue Inventory – MFI), anxiety and depression (Hospital 
Anxiety and Depression Scale – HADS), and sleep quality (Pittsburgh Sleep Quality Index – 
PSQI). Pulmonary rehabilitation health records were accessed to collect data on the remaining 
variables. The majority of the participants (61.9% - 81.0%) experienced moderate levels of 
subjective fatigue in all four dimensions. Moderate to severe levels of physical fatigue were 
experienced in 95.3% of the participants. The only significant relationship was between anxiety 
and emotional fatigue; all other relationships were statistically insignificant. There were no 
significant differences between sex, supplemental oxygen use, smoking status, and severity of 
dyspnea on the four dimensions of subjective fatigue. Many of the participants had probable 
presence of clinical anxiety (42.9%), where the prevalence of anxiety was nearly twice as high as 
depression (21.4%). Findings from this study can be used by healthcare professionals to gain a 
better understanding of fatigue in individuals with COPD who attend pulmonary rehabilitation, 
and help in developing effective interventions for reducing the distressing effects of fatigue. 
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CHAPTER 1 
Introduction 
1.1 Background and Significance of the Problem 
Fatigue is common in individuals with COPD (chronic obstructive pulmonary disease) 
and has been referred to as the most distressing or one of the most distressing symptoms 
experienced (Kinsmen, Fernandez, Schocket, Dirks, & Covino, 1983; Theander & Unosson, 
2004). Fatigue impacts negatively on functioning (Breslin et al., 1998; Gift & Pugh, 1993) in 
terms of quality of life, including physical, psychological, social, and cognitive functioning 
(Theander & Unosson).  
Four dimensions of subjective fatigue including: emotional, behavioural, cognitive, and 
physical, were examined in a group of individuals with COPD who attended an outpatient 
pulmonary rehabilitation program. The primary purpose of this study was to determine the 
proportion of individuals experiencing the four dimensions of fatigue, and to examine the 
relationships between these dimensions of fatigue and various influencing factors (dyspnea, 
depression, anxiety, sleep quality, activity limitation, heart rate, and oxygen saturation). The 
secondary purpose was to compare the four dimensions of fatigue by sex, supplemental oxygen 
use, smoking status, and severity of dyspnea, and to examine the relationships between the four 
dimensions of fatigue and age, the number of co-morbidities, and the amount of pulmonary 
rehabilitation received. The study was guided by a conceptual framework that was modified from 
the Theory of Unpleasant Symptoms (TOUS) (Lenz, Pugh, Milligan, Gift, & Suppe, 1997) to 
examine the relationships among various dimensions of subjective fatigue and the influencing 
factors. 
1.2 Statement of the Problem 
Given the high prevalence of COPD, the high occurrence of fatigue in individuals with 
COPD, and the significant impact fatigue has on these individuals’ quality of life, fatigue in 
COPD is an important area of focus for COPD research. Much controversy still exists today 
about the definition, the influencing factors, and the various dimensions of fatigue. Until more 
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 research is conducted on fatigue in individuals with COPD, these gaps in research and 
knowledge will remain. To the author’s knowledge, limited research has been conducted to 
examine various influencing factors of fatigue and the multidimensionality of fatigue in 
individuals with COPD. Most of the existing research on fatigue in COPD has focussed on 
quality of life or functional performance, and only one dimension: intensity of the fatigue. In 
addition, there are very few Canadian studies (Graydon & Ross, 1995; Graydon, Ross, Webster, 
Goldstein, & Avendano, 1995; Small & Lamb, 1999; Woo, 2000a; Woo, 2000b) that have 
examined fatigue in individuals with COPD. More research, however, has been conducted to 
examine fatigue in other chronic illnesses such as cancer.  
1.3 Statement of the Purpose 
To narrow the gap in research and knowledge, a feasibility study was conducted. The 
researcher examined the four dimensions of subjective fatigue (emotional, behavioural, 
cognitive, and physical) in a group of individuals with COPD who attended pulmonary 
rehabilitation on an outpatient basis in the Saskatoon Health Region. The primary purpose was to 
determine the proportion of individuals experiencing the four dimensions of fatigue, and to 
examine the relationships between each of the four dimensions of subjective fatigue, and some of 
the factors previously identified in the literature as influencing fatigue. These included: dyspnea, 
depression, anxiety, sleep quality, activity limitation, heart rate, and oxygen saturation. The 
secondary purpose was to compare the four dimensions of fatigue by sex, supplemental oxygen 
use, smoking status, and severity of dyspnea, and to examine the relationships between the four 
dimensions of fatigue and age, the number of co-morbidities, and the amount of pulmonary 
rehabilitation received. 
1.4 Research Questions 
The primary research questions were: 
• 1. What proportion of the individuals with COPD receiving pulmonary 
rehabilitation experienced emotional, behavioural, cognitive, and physical 
dimensions of subjective fatigue? 
• 2. What are the relationships between each of the four dimensions of subjective 
fatigue and various symptoms (dyspnea, depression, anxiety, sleep quality, 
activity limitation, heart rate, and oxygen saturation) in these individuals? 
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The secondary research questions were: 
• 1. How do men and women compare on the four dimensions of subjective 
fatigue? 
• 2. How do individuals who use supplemental oxygen and those who do not use 
supplemental oxygen compare on the four dimensions of subjective fatigue? 
• 3. How do ex-smokers, non-smokers, and those who currently smoke compare on 
the four dimensions of subjective fatigue? 
• 4. How do the individuals’ severity of dyspnea according to the Medical Research 
Council (MRC) Dyspnea Scale grades compare on the four dimensions of 
subjective fatigue? 
• 5. What are the relationships between the four dimensions of subjective fatigue 
and age, the number of co-morbidities, and the amount of pulmonary 
rehabilitation received? 
1.5 Assumptions 
 Assumptions made in this study included that all participants: answered the 
questionnaires truthfully, were able to answer the questions, and understood what they are being 
asked in the questions. The assumption of participants having felt that fatigue was a distressing 
symptom was based on previous studies. Other assumptions made in this study were that some 
participants were fatigued due to activities of daily living (ADLs) and exercise, and that some of 
the fatigue could not be controlled.  
1.6 Relevance and Significance 
In this study, the factors influencing fatigue in COPD and fatigue itself, which has not 
been studied in depth, were examined. The study can facilitate a better understanding of the 
factors influencing fatigue as well as the multidimensionality of fatigue in a group of individuals 
with COPD who receive pulmonary rehabilitation on an outpatient basis in the Saskatoon Health 
Region. Guided by the results of this study, the researcher’s knowledge translation methods such 
as providing participants with a summary of the study findings, presenting at conferences, and 
publishing the study in a scholarly journal, can spread awareness among clinicians, healthcare 
professionals, researchers, individuals with COPD and their families about the complex nature of 
fatigue. By building on this study, future studies can help develop effective interventions and 
 3
 management strategies in reducing the distressing effects of fatigue to help improve the quality 
of life in individuals with COPD. Examining the relationships of some influencing factors and 
various dimensions of fatigue was a step towards reducing fatigue in individuals with COPD. 
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CHAPTER II 
Review of the Literature 
2.1 The Concept of Fatigue 
Fatigue has been defined differently by various disciplines (Piper, 2003). Despite these 
numerous definitions of fatigue, there is no consensus on its definition (Aaronson et al., 1999; 
Groopman, 1998; Piper, 2004; Ream & Richardson, 1996), which poses a major challenge in 
measuring fatigue (Glaus, 1993; Glaus, Crow & Hammond, 1996). For the purpose of this study, 
Ream and Richardson’s (1996) definition of fatigue, which is from the nursing discipline was 
used. According to Ream and Richardson, “fatigue is a subjective, unpleasant symptom which 
incorporates total body feelings ranging from tiredness to exhaustion, creating an unrelenting 
overall condition which interferes with individuals’ ability to function to their normal capacity,” 
(p. 527). Other definitions of fatigue range from a subjective perception or sensation (Glaus; 
Glaus et al.), a “feeling of lack of energy and tiredness not related to muscle weakness” 
(Colombo et al., 2000, p. 506), the effects on functional performance (Curt, 2000a; Curt, 2000b), 
an underlying biological nature (Piper, 2003), the descriptions of the origin or cause (Piper, 
2003), to a clinical definition such as temporal patterns over time (Piper, Lindsey, & Dodd, 
1987). A major factor for the lack of a universal definition is that the underlying mechanisms are 
unknown (Piper, 2003). Lenz et al. (1997) refer to these underlying mechanisms as influencing 
factors in the TOUS. Another contributing factor to the lack of a universal definition is the 
growing consensus that fatigue is a complex, multidimensional sensation (Piper, 2003; Potempa, 
1993; Ream & Richardson, 1996). Due to these contributing factors, researchers and clinicians 
have various views about the signs, symptoms, indicators, outcomes, or effects of fatigue 
(Winningham et al., 1994).  
2.2 Dimensions of Fatigue 
There is an emerging consensus that fatigue is multidimensional (Piper, 2003; Potempa, 
1993; Ream & Richardson, 1996); however, there is no agreement on what those dimensions 
may be (Glaus, 1993; Piper, 2003; Winningham et al., 1994). Focusing on the 
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 multidimensionality of fatigue is considered to be important because comprehensive assessment 
of fatigue will facilitate the development of appropriate interventions and strategies (Piper, 
2003). Dimensions commonly cited are: severity (Woo, 2000a; Woo, 2000b;), behavioural, 
temporal, cognitive, sensory, affective, and physiological (Piper, 2003). The behavioural 
dimension includes indicators of changes in physical performance, ADLs, or the amount of effort 
needed to perform physically (Piper, 2003). The affective dimension, also referred to as the 
emotional or psychological dimensions, includes the emotional effects of fatigue (Piper, 2003). 
The cognitive dimension, also referred to as mental, consists of indicators of changes in thought 
or concentration (Piper, 2003). The sensory dimension, also referred to as the physical, general 
or somatic dimension, consists of signs and symptoms of fatigue including the location and the 
intensity of the fatigue experienced (Piper, 2003). The temporal dimension, consists of indicators 
of the timing, pattern, and duration of fatigue (Piper, 2003). Lastly, the physiological dimension 
includes the underlying mechanisms of fatigue (Piper, 2003). 
From the limited research focused on examining the multidimensionality of fatigue in 
individuals with COPD, a few studies identified the same four dimensions of subjective fatigue 
(emotional, behavioural, cognitive, and physical), which were examined in this study. The 
relationship between the four dimensions of subjective fatigue and various influencing factors, 
such as: pulmonary function (Breslin et al., 1998; Breukink et al., 1998); respiratory and 
peripheral muscle force, exercise capacity (Breukink et al., 1998); exercise tolerance, depression, 
and quality of life (Breslin et al., 1998) have been studied. Another study was conducted to 
examine fatigue in three other dimensions: frequency, intensity, and distress (Gift & Shepard, 
1999).  
2.3 Measurement of Fatigue 
 Many instruments have been developed by researchers and clinicians to measure fatigue. 
Some measure one dimension of fatigue while others are multidimensional. Some of the single-
dimensional instruments contain only one item, while others contain multiple items. There has 
been some criticism that single-item, single-dimensional intensity rating scales are less reliable 
than multi-item measures (Lee, Hicks, & Nino-Murcia, 1991). However, these single-item, 
single-dimensional intensity rating scales can be useful in the clinical setting, as they provide a 
quick method of screening individuals who may need more in-depth fatigue assessments, or 
when fatigue is required to be assessed frequently (Piper, 2003). Likert-type scales, numerical 
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 rating scales, and visual analogue scales (VAS) are commonly used single-item, single-
dimensional scales for fatigue (Piper, 2003). There are numerous multiple-item, single-
dimensional fatigue scales available. Some commonly used ones include the Brief Fatigue 
Inventory (BFI), Profile of Mood States Fatigue Subscale (POMS-F), Profile of Mood States 
Vigor Subscale (POMS-V), and Multidimensional Assessment of Fatigue (Piper, 2003). More 
complex fatigue scales are multidimensional, and some commonly cited ones are: Fatigue Impact 
Scale, Multidimensional Fatigue Inventory (MFI), and Piper Fatigue Scale-Revised (PFS-R) 
(Piper, 2003). Some of these multidimensional scales are lengthy, and may not be appropriate for 
individuals with COPD who may be experiencing fatigue. Therefore, choosing which fatigue 
scale to use for a study with persons with COPD should be considered carefully. 
2.4 Factors Associated with Fatigue 
Various factors have been found to be associated or predictive of fatigue in various 
populations. These factors include: age (Piper, 2003), anemia (Breitbart, McDonald, Rosenfeld, 
Monkman, & Passik, 1998; Mendoza et al., 1999), co-morbidities (Glaus et al., 1996; Loge, 
Ekeberg, & Kaasa; 1998), weakness and muscle wasting (Burns, 1991; Sliwa, 2000), 
medications (Piper, 2004), morbidity (Dunbar et al., 1999), mortality (Irvine et al., 1999), 
ethnicity (Lee, 1999; Lee, 2001), symptom burden and distress (Cimprich & Ronis, 2001; Irvine, 
Vincent, Graydon, Bubela, & Thompson, 1994), and quality of life (Curt, 2000a; Ream & 
Richardson, 1997). In addition, there have been conflicting results on the relationship between 
fatigue and several factors including: disease characteristics (Bakshi et al., 1999; Glaus et al., 
1996; Groopman, 1998; Sliwa, 2000), depression and anxiety (Epstein, 1995), sex (Nardini, 
1995; Piper, 2003), and socioeconomic status (Ang & Calabrese, 1999; Knobel et al., 2001). 
2.5 Fatigue in Persons with COPD 
Of the various symptoms individuals with COPD experience (Gift & Pugh, 1993), fatigue 
has been found to be common and distressing in these individuals (Gift & Shepard, 1999; 
Graydon & Ross, 1995; Graydon et al., 1995; Janson-Bjerklie, Carrieri, & Hudes, 1986; 
Kinsman et al., 1983; Theander & Unosson, 2004). COPD has a high prevalence, reported by the 
Canadian Lung Association (2008, ¶ 21), where 1.5 million Canadians have been diagnosed with 
COPD. In 2003, COPD was the fourth leading cause of death in Canada (O’Donnell et al., 2008). 
Furthermore, COPD is continuing to rise and is estimated to be the third leading cause of death 
in the world by the year 2020 (Canadian Lung Association, ¶ 22). COPD is a chronic lung 
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 disease that is usually caused by smoking and characterized by shortness of breath, increased 
sputum production, and coughing (Canadian Lung Association, ¶ 1, 3). The effects of fatigue are 
substantial to the individual with COPD. Fatigue significantly impairs functioning (Breslin et al., 
1998; Gift & Pugh, 1993) in terms of quality of life, including physical, psychological, social, 
and cognitive functioning (Theander & Unosson). As demonstrated, fatigue is a significant 
problem for individuals with COPD. However, pulmonary rehabilitation has been found to be 
effective in reducing fatigue and dyspnea according to a meta-analysis conducted by Lacasse, 
Maltais, and Goldstein (2004). 
Fatigue in individuals with COPD is common and has been referred by these individuals 
as the worst or one of the worst symptoms experienced. Kinsman et al. (1983) found that over 
58% of the individuals had experienced fatigue “almost always” or “always.” In a newer study 
conducted by Theander and Unosson (2004) comparing fatigue in individuals with COPD with a 
control group, 47.2% of the individuals with COPD reported experiencing fatigue every day 
during the previous month. Over half of these individuals (57.2%) experienced fatigue for more 
than six hours, and 44.4% of these individuals reported that fatigue was either their worst or one 
of their worst symptoms. Subjective fatigue is negatively related to functional performance in 
individuals with COPD (Breslin et al., 1998; Graydon & Ross, 1995; Graydon et al., 1995; 
Reishtein, 2005; Theander & Unosson). Theander and Unosson found that fatigue in individuals 
with COPD significantly impacted their cognitive, social, and psychosocial functioning. In a 
qualitative study conducted in Canada, participants with COPD described fatigue as a feeling of 
general tiredness that occurred every day and affected their social, physical and emotional 
functioning (Small & Lamb, 1999). In another qualitative study using a phenomenological 
approach, participants with COPD and cancer described fatigue as being exhausted and drained 
in energy which affected their daily activities, social and working life (Ream & Richardson, 
1997). These participants’ fatigue created frustration and loss of control in their lives (Ream & 
Richardson, 1997). In a study conducted by Kapella, Larson, Patel, Covey, and Berry (2006), 
fatigue, dyspnea, airflow obstruction, and anxiety accounted for 36% of the variance in 
functional performance. 
Fatigue is often related to dyspnea (Janson-Bjerklie et al., 1986; Kapella et al., 2006; 
Kinsman et al., 1983; Reishtein, 2005). Dyspnea was found to have a strong relationship with 
fatigue in two studies, one conducted by Kinsman et al. (r = 0.76), and the other study conducted 
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 by Kapella et al. (r = 0.74). In another study, dyspnea was found to have a moderate relationship 
with fatigue (r = 0.43) (Reishtein). Janson-Bjerklie et al. found that dyspnea was related to 
fatigue to the extent that 45% of the subjects described their dyspnea as fatigue. 
Fatigue is also related to other problems reported by individuals with COPD, such as 
depression, anxiety, sleep quality (Gift & Shepard, 1999; Kapella et al., 2006; Reishtein, 2005), 
and negative mood (Small & Graydon, 1992). Kapella et al. observed that dyspnea, depression, 
and sleep quality accounted for 42% of the variance in subjective fatigue. Similarly, Small and 
Graydon (1992) found that fatigue was related to negative mood, where fatigue explained 28% 
of the variance in negative mood. Reishtein observed a weak relationship between sleep quality 
and fatigue (r = 0.19). Gift and Shepard found that a moderate relationship existed between 
psychological factors and fatigue (r = 0.59).  
A Canadian pilot study conducted by Woo (2000a) examined the relationships between 
dyspnea, physical activity, and fatigue in patients with COPD. Dyspnea, physical activity, and 
fatigue were found to be all significantly inter-related. Since this was a pilot study, results cannot 
be generalized because of its small sample size (N = 15) and use of convenience sampling. In 
addition, this study examined fatigue in only one dimension: intensity. In another Canadian study 
also conducted by Woo (2000b), the mediating effects of physical activity between dyspnea and 
fatigue in patients with COPD were examined. A larger sample size of 39 patients was obtained; 
however, a similar limitation is the use of convenience sampling. After controlling for age and 
FEV1 (forced expiratory volume in one second), Woo (2000b) found that dyspnea, physical 
activity, and fatigue were all inter-related. Further analysis suggested that physical activity acted 
as a mediator between dyspnea and fatigue. This study examined fatigue in terms of the intensity 
dimension.  
From the limited literature available which examines the multidimensionality of fatigue 
in individuals with COPD, Breukink et al. (1998) measured: FEV1, vital capacity (VC), maximal 
inspiratory peak pressure (Pimax), symptom-limited bicycle exercise capacity (maximum 
workload), and maximal voluntary isometric muscle force of several muscles. These researchers 
found a negative relationship between two dimensions of the Multidimensional Fatigue 
Inventory (MFI): reduced activity and FEV1 (r = -0.62), and motivation and FEV1 (r = -0.55).  No 
relationship was observed between any of the dimensions of fatigue and maximum workload. In 
addition, the physical fatigue dimension was related to the majority of the muscle forces 
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 measured. Based on the results, the authors claimed that in individuals with COPD, the activity 
and physical dimensions of subjective fatigue were related to pulmonary function and skeletal 
muscle force. A limitation of this study was the small same size (N = 19), where the 
generalizability of the findings from the study can be decreased. 
In another study that examined the multidimensionality of fatigue in individuals with 
COPD, Breslin et al. (1998) also used the MFI. These researchers measured: pulmonary 
function, exercise tolerance, depression, and quality of life in individuals with COPD. The 
general fatigue dimension of the MFI was related to FEV1 (r = -0.32), exercise tolerance (r =      
-0.55), depression (r = 0.44), and overall quality of life (r = 0.75). Depression was also related to 
another dimension of the MFI: mental fatigue. The physical dimension of the MFI was related to 
increased pulmonary impairment and reduced exercise tolerance. The cognitive dimension was 
not observed to be highly related to the physical dimension of quality of life. In addition, all five 
dimensions of fatigue in the MFI were found to be related to overall impairment in quality of 
life. This study conducted by Breslin et al. had a small same size (N = 41) and used convenience 
sampling; however, the samples were drawn from two different countries (United States and 
Netherlands). The authors claimed that the dimensions of fatigue were related to pulmonary 
function, exercise tolerance, and quality of life.  
A study conducted by Gift and Shepard (1999) examined fatigue in the following 
dimensions: frequency, intensity, and distress, which are outlined in the TOUS. Women and men 
both experienced a moderate level of fatigue and no significant differences were observed. 
However, there were differences in all three dimensions of fatigue between the two genders. 
Other symptoms frequently reported included dyspnea and cough. Both genders were similar in 
psychological symptoms with the exception of anxiety which was higher in women. The 
predictors of fatigue in both genders included dyspnea and physical symptoms, which predicted 
42% of the variance. 
2.6 Fatigue in Other Illnesses 
Fatigue has been studied more extensively in cancer and other chronic illnesses such as 
heart failure, Human Immunodeficiency Virus (HIV), and rheumatoid arthritis. This related 
literature is explored briefly in this section. Krishnasamy (1997, 2000) explored the nature and 
impact of fatigue in advanced cancer in a qualitative study. This study found that the fatigue 
experienced by the participants was unpredictable, overwhelming, brought feelings of 
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 helplessness and hopelessness. A study conducted by Blesch et al. (1991) examined fatigue and 
its correlates in individuals with breast and lung cancer. Fatigue was significantly related to level 
of pain and scores on the Profile of Mood States (POMS). A limitation of this study was its small 
sample size (N = 77) and use of convenience sampling, which limits the generalizability of the 
findings.  
Friedman and King (1995) examined the amount of variance in fatigue accounted for by 
psychological factors and physical symptoms in older women with heart failure at two different 
time periods. Fatigue occurred frequently at both time periods. Physical symptoms contributed to 
the variance in fatigue at both time periods, whereas psychological factors did not. The physical 
symptoms which contributed uniquely to the variance in fatigue included: sleep difficulties, chest 
pain, weakness, and dyspnea.  
In a study that examined fatigue in women with HIV, Lee, Portillo, and Miramontes 
(1999) found that morning fatigue was related to wake episodes during the night, napping, and 
perception of sleep disturbance during the past week. Furthermore, Lee et al. discovered that a 
predictor of the severity of fatigue experienced the next evening was the number of awakenings 
during the first night. Although Lee et al. used a larger sample size (N = 100), they used 
convenience sampling.  
Belza, Henke, Yelin, Epstein, and Gilliss (1993) examined the prevalence of fatigue, and 
identified correlates of fatigue in a group of older adults with rheumatoid arthritis. The 
prevalence of fatigue was high, remained constant, and affected some ADLs. In addition, Belza 
et al. observed that pain rating, functional status, sleep quality, the female gender, co-
morbidities, and duration of disease explained a significant amount of variance in fatigue. In 
another study comparing fatigue in healthy individuals and individuals with rheumatoid arthritis, 
Belza (1995) also examined the relationships between fatigue and variables including: pain, 
sleep, functional status, depressive symptoms, and disease activity. Fatigue was higher in 
individuals with rheumatoid arthritis compared to the healthy individuals. Fatigue was strongly 
related to poor sleep, functional disability, greater pain, more depressive symptoms, and lower 
hematocrit (Hct). The sample size in this study was not small (N = 97); however, convenience 
sampling was used.  
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 2.7 Pulmonary Rehabilitation in Persons with COPD 
 Pulmonary rehabilitation should be encouraged in clinically stable COPD patients who 
although are receiving medications to help manage their COPD, remain dyspneic and limited in 
their exercise capacity (O’Donnell et al., 2008). The effects of pulmonary rehabilitation are 
beneficial, where patients experience improved exercise capacity, increased quality of life, 
decreased risk of hospitalizations after an acute exacerbation of COPD (O’Donnell et al., 2008), 
reduced dyspnea (Lacasse et al., 2004; O’Donnel et al., 2008), and reduced fatigue (Lacasse et 
al.). 
2.8 Psychometric Evaluation of Instruments 
 There are valid and reliable instruments designed to measure various dimensions of 
fatigue, as well as the influencing factors that were examined in this study. Validity and 
reliability of instruments including the: Multidimensional Fatigue Inventory (MFI), MRC 
Dyspnea Scale, six-minute walk test (6MWT), Hospital Anxiety and Depression Scale (HADS), 
and Pittsburgh Sleep Quality Index (PSQI) are discussed in the following section. 
2.8.1 Fatigue 
 The MFI was developed by Smets, Garssen, Bonke, and de Haes (1995). The MFI has 
been tested for its psychometric properties by the developers of the instrument in cancer patients, 
patients with chronic fatigue syndrome, psychology students, medical students, army recruits, 
and junior physicians. In another study, Smets, Barssen, Cull, and de Haes (1996) further 
evaluated the psychometric properties of the MFI in cancer patients. All authors found that the 
MFI had good internal consistency, with an average Cronbach’s alpha of 0.84 in the first study 
(Smets et al., 1995), and a Cronbach’s alpha between 0.79 and 0.93 (Smets et al., 1996) in the 
second study. The MFI had good construct validity where results showed significant differences 
between groups of subjects for all subscales (Smets et al., 1995). Significant correlations 
between the MFI and ADLs, anxiety, and depression scores, also demonstrated satisfactory 
construct validity (Smets et al., 1996). Convergent validity was satisfactory and results 
demonstrated correlation with a visual analogue scale (VAS) (Smets et al., 1995; Smets et al., 
1996) (r = 0.23 – 0.77), and with the Rotterdam Symptom Checklist (r = 0.54 – 0.83) (Smets et 
al., 1996). The MFI is also available in over 10 languages (Smets et al., 1995). The MFI has been 
used in various clinical populations, including lung disorders, and in the healthy population 
(Smets et al., 1995). 
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  Similar validity and reliability results for the MFI were found in one study by Hagelin, 
Wengstrom, Runesdotter, and Furst (2007), and in another study by Gentile, Delaroziere, 
Sambuc, and San Marco (2003). The psychometric properties of the Swedish version of the MFI 
was tested in four populations: palliative care patients, cancer patients, non-cancer outpatients, 
and hospital staff (Hagelin et al.), and the psychometric properties of the French version of the 
MFI was evaluated in thyroid patients and patients from a fatigue centre (Gentile et al.). Similar 
to Smets et al. (1995, 1996), Hagelin et al. and Gentile et al. also found that the MFI was a valid 
and reliable instrument for measuring fatigue. Few participants omitted items in the MFI (Gentile 
et al.; Hagelin et al.) which led Hagelin et al. to believe that the acceptability was high. 
Convergent validity was good as demonstrated from the high correlation between the scores of 
all the subscales in the MFI and the Category Ratio instrument (CR-10) (r = 0.37 – 0.74) 
(Hagelin et al.), and the high correlation between the MFI and a VAS (Gentile et al.). Cronbach’s 
alpha for the MFI ranged between 0.67 and 0.94 (Hagelin et al.), and between 0.68 and 0.93 
(Gentile et al.), showing good internal consistency. In addition, the MFI had good internal 
consistency as shown by the inter-item correlation coefficients (r = 0.21 – 0.90) (Hagelin et al.). 
In the participants who were followed one month after the start of the study, the reproducibility 
and sensitivity to change demonstrated satisfactory results (Gentile et al.). 
2.8.2 Dyspnea  
 The MRC Dyspnea Scale was developed to measure the effect of breathlessness on 
performing daily activities (Fletcher, 1960). A study conducted by Bestall et al. (1999) examined 
the validity of the MRC Dyspnea scale in COPD patients. Various assessments were used to 
determine whether there were significant correlations between the grades obtained in the MRC 
Dyspnea Scale and these assessments. Significant correlations were found between the MRC 
Dyspnea Scale grades and the shuttle walking test, the St. George’s Respiratory Questionnaire 
(SGRQ), the Chronic Respiratory Questionnaire (CRQ), and the Nottingham Extended Activities 
of Daily Living (EADL). Bestall et al. (1999) concluded that the MRC Dyspnea Scale was a 
valid and simple tool to use in COPD patients. High inter-rater reliability has been found in the 
MRC Dyspnea Scale where the Cohen’s kappa value was 0.92 (Mahler & Wells, 1988). Various 
studies have been conducted to examine the concurrent validity of the MRC Dyspnea Scale and 
has been found to be satisfactory in individuals with respiratory conditions (Darbee & Ohtake, 
2006). The grades on the MRC Dyspnea Scale correlated with other dyspnea measurement tools 
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 such as the Oxygen Cost Diagram (r = -0.53) and the Baseline Dyspnea Index (r = -0.70) in 
asthma patients (Mahler & Wells), and the SGRQ (r = 0.53 – 0.70) in COPD patients (Hajiro, 
Nishimura, Tsukino, Ikeda & Oga, 2000). The MRC Dyspnea Scale grades correlated with PFTs 
(pulmonary function tests) such as forced vital capacity (FVC) (r = -0.28) (Guyatt, Townsend, 
Keller, Singer, & Nogradi, 1989) in COPD patients, and with the 6MWT (r = -0.52) (Mak, 
Bugler, Roberts, & Spiro, 1993). In addition, in patients with moderately severe COPD, the 
MRC Dyspnea Scale grades reduced after receiving six weeks of pulmonary rehabilitation, 
which was found to be both clinically and statistically significant (Lorenzi et al., 2004).  
2.8.3 Activity Limitation 
  The 6MWT is a useful test for measuring functional exercise for daily physical activities 
(American Thoracic Society, 2002). Exploring the possibility of shortening the 12MWT to a 
6MWT was performed by Butland, Pang, Gross, Woodcock and Geddes (1982). Various studies 
have examined the reliability and validity of the 6MWT not only in COPD patients, but also in 
pediatric patients, surgical patients, patients with heart failure, patients with pacemakers, and 
peripheral arterial disease patients (Solway, Brookes, Lacasse, & Thomas, 2001). Several studies 
have found the 6MWT to have satisfactory construct and concurrent validity. In COPD patients 
and patients with severe asthma, the 6MWT correlated with several lung diffusion tests and 
pulmonary function tests (r = 0.48 – 0.63) (Mak, Bugler, Roberts, & Spiro, 1993). In this study, 
the 6MWT also correlated with the MRC Dyspnea Scale (r = -0.52) (Mak et al.). Similarly, in a 
study conducted by Wijkstra et al. (1994) which studied adults with COPD, the 6MWT 
correlated with several lung diffusion tests and pulmonary function tests (r = 0.50 – 0.62). The 
6MWT also correlated with the Borg scale (r = -0.41) (Wijkstra et al., 1994). A study conducted 
by Bernstein et al. (1994) which examined elderly men with moderate COPD, found that the 
distance walked in the 2MWT, 4MWT, 6MWT, and 12MWT correlated with maximal oxygen 
consumption (r = 0.45, 0.48, 0.51, and 0.49, respectively). Bernstein et al. (1994) also found that 
the 2MWT, 4MWT, 6MWT, and 12MWT correlated with maximal carbon dioxide elimination (r 
= 0.35, 0.36, 0.40, and 0.38, respectively). More reliability evaluation of the 6MWT can be 
found in studies examining other clinical populations.  
2.8.4 Depression and Anxiety 
 The HADS was developed by Zigmond and Snaith (1983). The psychometric properties 
of the HADS have been evaluated in various clinical populations including psychiatric patients 
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 (Bramley, Easton, Morley, & Snaith, 1988), cancer patients (Moorey et al., 1991), and patients 
with physical illnesses (Aylard, Gooding, & McKenna, 1987). The HADS has been found to 
have good internal consistency (Zigmond & Snaith) with a Cronbach’s alpha of 0.93 for the 
anxiety subscale, and 0.90 for the depression subscale (Moorey et al., 1991). In addition, the 
HADS has been used in studies involving: general medicine outpatients (Soderstrom & Grimm, 
2004), individuals with chronic illnesses (Payne, 1992), and individuals with cardiac conditions 
(Soderstrom & Grimm). Zigmond and Snaith reported the internal consistency of the two 
subscales with the item-to-subscale reliability (r = 0.41 – 0.76 for the anxiety items, and r = 0.30 
– 0.60 for the depression items). The subscales and psychiatric ratings correlated (r = 0.74 for 
anxiety and 0.70 for depression) demonstrating that the subscales could be used as indicators of 
anxiety and depression. In a review of the psychometric properties available for the HADS by 
Herrmann (1997), the HADS is a reliable and valid instrument for measuring depression and 
anxiety in clinical populations. The HADS has been validated in various languages in different 
populations, and is generally well accepted by the subjects (Herrmann). In a new update on the 
validity of the HADS, a common conclusion from 747 studies was that “the HADS was found to 
perform well in assessing severity and caseness of anxiety disorders and depression in both 
somatic, and psychiatric and primary care patients and the general population” (Bjelland, Dahl, 
Haug & Neckelmann, 2002, p. 69). 
2.8.5 Sleep Quality 
 The PSQI was developed by Buysse, Reynolds, Monk, Berman, and Kupfer (1989). 
Reliability and validity were evaluated for the PSQI by its developers in a study with different 
clinical populations including individuals with major depressive disorders, individuals diagnosed 
with either Disorder of Initiating and Maintaining Sleep (DIMS) or Disorder of Excessive 
Somnolence (DOES), and healthy controls (Buysse et al.). The subjects found the PSQI easy to 
understand and use. Cronbach’s alpha for all seven components of the PSQI in this study was 
0.83, demonstrating a high internal consistency. High test-retest reliability of the overall PSQI 
showed a correlation of 0.85. To assess validity, PSQI scores were compared between the 
healthy controls, the individuals with major depressive disorders, and the individuals with the 
sleep disorders. The PSQI scores in individuals with the major depressive disorders and the 
individuals with the sleep disorders were distinguishable from the healthy controls. In addition, 
concurrent validity was demonstrated through polysomnographic findings. The PSQI is available 
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 in several different languages (Smyth, 2008). A study by Carpenter & Andrykowski (1998) 
examined the psychometric properties of the PSQI in four clinical populations including: bone 
marrow transplant patients, renal transplant patients, women with breast cancer, and women with 
benign breast problems. Good internal consistency was found across all groups of subjects, 
where the global Cronbach’s alpha was 0.80. The global PSQI scores and component scores 
were correlated (r = 0.42 – 0.83). Construct validity was evaluated in terms of convergent and 
discriminant validity as demonstrated by the consistent correlations with both related and 
unrelated constructs across all groups of subjects. 
2.9 Summary 
There is no consensus on the definition of fatigue due to debate on the various 
dimensions of fatigue and its associated underlying mechanisms or influencing factors. 
Researchers in a few studies found that fatigue was either the most distressing or one of the most 
distressing symptoms experienced in COPD (Kinsman et al., 1983; Theander & Unosson, 2004). 
In addition, in various studies, subjective fatigue was found to be negatively related to functional 
performance in individuals with COPD (Breslin et al., 1998; Graydon & Ross, 1995; Graydon et 
al., 1995; Kapella et al., 2006; Ream & Richardson, 1997; Reishtein, 2005; Small & Lamb, 
1999; Theander & Unosson). Fatigue is often related to dyspnea and other problems reported by 
individuals with COPD, such as depression, anxiety, and sleep quality (Gift & Shepard, 1999; 
Graydon & Ross; Janson-Bjerklie et al., 1986; Kapella et al.; Kinsman et al., 1983; Reishtein). 
Two Canadian studies, conducted by Woo (2000a; 2000b) found that fatigue was related to 
physical activity and dyspnea. These two studies conducted by Woo examined just one 
dimension of fatigue: intensity. Limited research has been conducted to examine different 
influencing factors of fatigue and the multidimensionality of fatigue in individuals with COPD. 
However, fatigue has been studied more extensively in other chronic illnesses. As explored in 
this review of the literature, there are several advantages to pulmonary rehabilitation. There are 
also valid and reliable instruments available to measure the different variables of interest that 
were examined in this study. 
2.10 Gaps in the Research 
Limited research has been conducted to examine various influencing factors of fatigue 
and the multidimensionality of fatigue in individuals with COPD. This study was different from 
the studies in the review of the literature which examined the multidimensionality of fatigue in 
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 individuals with COPD, in that dyspnea, anxiety, sleep quality, heart rate, and oxygen saturation 
were studied. Most of the existing research on fatigue in COPD have focused on quality of life or 
functional performance, and only one dimension of fatigue: intensity. In addition, there are very 
few Canadian studies that have examined fatigue in individuals with COPD.  
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CHAPTER III 
Conceptual Framework 
 The conceptual framework that was used to guide this study in examining the 
relationships among various dimensions of subjective fatigue and influencing factors of fatigue 
was modified from the Theory of Unpleasant Symptoms (TOUS), developed by Lenz, Pugh, 
Milligan, Gift, and Suppe in 1995, and later revised in 1997. The influencing factors of the 
symptom experience in this theory are categorized into three factors: physiologic, psychologic, 
and situational (Lenz et al., 1997). According to TOUS, physiologic factors include pathology, 
trauma, and individuals’ level of energy (Lenz et al.). Psychologic factors include individuals’ 
mental state or mood, affective reaction to illness, and the level of uncertainty about their 
symptoms experienced and the possible meaning (Lenz et al.). Situational factors include social 
and physical aspects of the environment that may affect the individuals’ experience of the 
symptoms (Lenz et al.).  
In this study, the symptom being examined according to this theory was subjective 
fatigue. A modified framework for the proposed study was developed by the researcher which 
conceptualized subjective fatigue in four dimensions: emotional, behavioural, cognitive and 
physical. The influencing factors of fatigue were the three factors conceptualized in TOUS that 
were examined, which included: physiologic, psychologic, and situational. Under the physiologic 
factors were: dyspnea, activity limitation, heart rate, and oxygen saturation. Within the 
psychologic factors were depression and anxiety, and under the situational factors was sleep 
quality. The relationships between each of these influencing factors with each of the subjective 
fatigue dimensions was examined in this study. A diagram of this modified conceptual 
framework is displayed in Figure 3.1.  
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Adapted from the Theory of Unpleasant Symptoms (Lenz, Pugh, Milligan, Gift & Suppe, 1997). 
 
 
Figure 3.1. Conceptual Framework Displaying the Relationships among Various Dimensions of Subjective Fatigue and 
Influencing Factors of Fatigue  
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 3.1 Definitions of Research Variables 
 The variables that were examined in this study, including the conceptual and operational 
definitions are discussed in the next section. More detailed discussion on the instruments that 
were used to measure the variables are discussed in the methods and procedures section. 
3.1.1 Subjective Fatigue 
 Conceptual definition. Fatigue was defined as “a subjective, unpleasant symptom which 
incorporates total body feelings ranging from tiredness to exhaustion, creating an unrelenting 
overall condition which interferes with individuals’ ability to function to their normal capacity,” 
(Ream & Richardson, 1996, p. 527). 
 Operational definition. Subjective fatigue was measured using the MFI, which was 
distributed to the participants. The dimensions that were measured in the MFI included: 
emotional, behavioural, cognitive, and physical. The emotional dimension included the 
emotional effects of fatigue (Piper, 2003). The behavioural dimension was comprised of 
indicators of changes in physical performance, ADLs, or the amount of effort to perform 
physically (Piper, 2003). The cognitive dimension consisted of indicators of changes in thought 
or concentration (Piper, 2003). The physical dimension included the signs and symptoms of 
fatigue, and the intensity of the fatigue experienced (Piper, 2003). Piper (2003) noted that 
another term for the physical dimension is general fatigue. 
3.1.2 Physiologic Factor – Dyspnea 
Conceptual definition. Dyspnea was defined as difficult or laboured breathing (Gift & 
Pugh, 1993), or the symptom of shortness of breath (Scott, 2004). Dyspnea may arise during 
exercise or at rest in acute and chronic diseases (Scott). 
 Operational definition. Dyspnea was measured using the MRC Dyspnea Scale. The most 
recent grade obtained from the MRC Dyspnea Scale was found in the participants’ pulmonary 
rehabilitation health records and were recorded on a chart abstraction sheet by the researcher. 
The MRC Dyspnea Scale grades were recorded in the chart at various assessment time intervals 
which included: preliminary, three months, six months, and 12 months, in an interview format by 
the pulmonary rehabilitation staff. 
3.1.3 Physiologic Factor – Activity Limitation 
 Conceptual definition. Activity limitation was defined as the participants’ ability to 
engage in activity.  
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  Operational definition. Activity limitation was measured using the six-minute walk test 
(6MWT). The most recent distance participants had walked in the 6MWT were found in the 
participants’ pulmonary rehabilitation health records. The distances from the 6MWT for 
participants were recorded on a chart abstraction sheet by the researcher. The distances were 
recorded in the health record at various assessment time intervals which included: preliminary, 
three months, six months, and 12 months, in an interview format by the pulmonary rehabilitation 
staff. 
3.1.4 Physiologic Factor – Heart Rate 
 Conceptual definition. Heart rate was defined as the number of contractions of the heart 
muscle (heart beats) per unit of time. 
 Operational definition. Heart rate was measured by the number of heart beats per minute, 
which was measured by either the participant or the pulmonary rehabilitation staff, and recorded 
in his or her pulmonary rehabilitation health record. 
3.1.5 Physiologic Factor – Oxygen Saturation 
 Conceptual definition. Oxygen saturation was defined as “the amount of oxygen bound to 
hemoglobin in the blood, expressed as a percentage of the maximal binding capacity” (O’Toole, 
1997, p. 1443). 
 Operational definition. Oxygen saturation was measured with pulse oximetry, which was 
measured by either the participant or the pulmonary rehabilitation staff, and recorded in his or 
her pulmonary rehabilitation health record. 
3.1.6 Psychologic Factor – Depression and Anxiety 
 Conceptual definitions. Depression was defined as feelings of sadness that were 
persistent and interfered with normal daily functioning (National Institute of Mental Health, 
2008, ¶ 1). Anxiety was defined as excessive dread of situations that interfered with normal daily 
functioning (National Institute of Mental Health, 2008, ¶ 1).   
 Operational definitions. Depression and anxiety were measured using the Hospital 
Anxiety and Depression Scale (HADS), which was distributed to the participants.  
3.1.7 Situational Factor – Sleep Quality 
 Conceptual definition. Sleep quality was defined subjectively by the participants as the 
quality of sleep experienced. 
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  Operational definition. Sleep quality was measured using the Pittsburgh Sleep Quality 
Index (PSQI), which was distributed to the participants.  
3.1.8 Extraneous Variable – Smoking Status 
 Conceptual definition. Smoking status was defined by whether an individual smoked, did 
not smoke, or used to smoke in the past. 
 Operational definition. Data on smoking status was gathered from each participant’s 
pulmonary rehabilitation health record and recorded on a chart abstraction sheet by the 
researcher. Smoking status was classified as: non-smoker, currently smoking, or ex-smoker. The 
data for smoking status was recorded in the health record during the preliminary assessment in 
an interview format by the pulmonary rehabilitation staff. 
3.1.9 Extraneous Variable – Amount of Pulmonary Rehabilitation Received 
 Conceptual definition. The amount of pulmonary rehabilitation received was defined as 
the length of time a participant had attended pulmonary rehabilitation.  
Operational definition. Data on the initial assessment date which were recorded on the 
preliminary assessment by the pulmonary rehabilitation staff, were gathered from each 
participant’s pulmonary rehabilitation health record and recorded on a chart abstraction sheet by 
the researcher. The date of the first day a participant began attending pulmonary rehabilitation 
was recorded by day, month, and year.  
3.1.10 Extraneous Variable – Age 
 Conceptual definition. Age was defined by the length of time in years a participant has 
existed. 
 Operational definition. Data on age was gathered from each participant’s completed 
demographic form. Participants recorded the number of years from their date of birth. 
3.1.11 Extraneous Variable – Sex 
 Conceptual definition. Sex was defined as how each participant referred to himself or 
herself as either male or female. 
 Operational definition. Data on sex was gathered from each participant’s completed 
demographic form. Participants recorded how they referred to himself or herself as either male or 
female. 
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 3.1.12 Extraneous Variable – Co-morbidities 
 Conceptual definition. Co-morbidities were defined as any co-existing disease states 
(O’Toole, 1997).  
 Operational definition. Data on co-morbidities, excluding the diagnosis of COPD, were 
gathered from each participant’s pulmonary rehabilitation health record and recorded on a chart 
abstraction sheet by the researcher. Co-morbidities were recorded in the health record as medical 
history during the preliminary assessment in an interview format by the pulmonary rehabilitation 
staff. The number of co-morbidities was recorded.  
3.1.13 Extraneous Variable – Supplemental Oxygen Use 
 Conceptual definition. Supplemental oxygen use was defined as receiving any form of 
supplemental oxygen. 
 Operational definition. Data on supplemental oxygen use was gathered from each 
participant’s pulmonary rehabilitation health record and recorded on a chart abstraction sheet by 
the researcher. Supplemental oxygen use was classified as used supplemental oxygen, or did not 
use supplemental oxygen. Supplemental oxygen use was recorded in the health record during the 
preliminary assessment in an interview format by the pulmonary rehabilitation staff. 
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CHAPTER IV 
Methods and Procedures 
4.1 Research Design 
 Since limited research has been conducted to examine various influencing factors of 
fatigue and the multidimensionality of fatigue in individuals with COPD, a feasibility study was 
chosen. A feasibility study can help evaluate whether the selected instruments and other aspects 
of the methods and procedures used in the study were appropriate for studying fatigue in 
individuals receiving pulmonary rehabilitation. The reviewed literature that was conducted to 
examine influencing factors of subjective fatigue in individuals with COPD have used 
descriptive, cross-sectional designs.  
4.2 Setting 
 This study was conducted in pulmonary rehabilitation facilities (Confederation Mall and 
the Field House locations) in the city of Saskatoon, Canada. The self-report questionnaires, 
which were distributed by the researcher, were completed by the participants on a one-to-one 
basis with the researcher during their pulmonary rehabilitation sessions. 
4.3 Population and Sample 
 The target population consisted of individuals with COPD receiving pulmonary 
rehabilitation in Saskatoon. Inclusion criteria included participants who: (a) had a confirmed 
diagnosis of COPD by a physician, (b) attended pulmonary rehabilitation in Saskatoon, (c) 
resided in Saskatchewan, (d) were able to read, write, understand, and communicate in English, 
and (e) were adults who were 18 years of age and older. 
Convenience sampling method was used because of its feasibility. It is, however, 
important to note that controlling for bias is difficult when using convenience sampling, and is 
considered a weak approach to sampling (Burns & Grove, 2005). Since limited research has been 
conducted in this area, convenience sampling was believed to be appropriate. Future studies can 
build on this study and utilize other sampling methods to reduce bias, such as random sampling. 
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 A sample size between 36 and 62 participants was determined by a sample size 
calculation with a standard power of 80%, r between 0.45 and 0.35, respectively, and a two-
tailed test with an alpha of 0.05 (Hulley et al., 2001). In another sample size calculation, a 
sample size between 48 and 82 participants was determined with a power of 90%, r between 0.45 
and 0.35, respectively, and a two-tailed test with an alpha of 0.05 (Hulley et al., 2001). 
Correlational analysis was used to calculate these sample sizes, which were based on the MFI. 
These calculations were based on a study conducted by Breslin et al. (1998).  
4.4 Ethical Considerations 
 Prior to the start of the study, a meeting with the Saskatoon Health Region’s pulmonary 
rehabilitation coordinator and manager was arranged to discuss the details of the study. The 
research proposal was submitted for approval to the University of Saskatchewan Behavioural 
Research Ethics Board, and approval was received on October 9, 2008 (Appendix A). 
Application was then made to the Saskatoon Health Region’s Ethics Board for operational 
approval, and approval was obtained on October 17, 2008 (Appendix B). During the process of 
participant recruitment, the researcher ensured that the participants understood the information 
contained in the brochure and consent form (Appendix C and D). Participants’ names did not 
appear on any of the questionnaires, demographic forms (Appendix E), or chart abstraction 
sheets (Appendix F) except for the consent forms and the Request for Results from Research 
Study forms (Appendix G). Each participant had a unique identification number on all 
questionnaires, demographic form, and chart abstraction sheet, which helped the researcher keep 
track of the completed forms. The consent forms, Master List of Participants and Associating 
Unique Identification Numbers (Appendix H), and the Request for Results from Research Study 
forms were stored separately from other information collected, so that it was not be possible to 
associate a name with any information. The data collected was entered into the computer with 
only the participants’ unique identification numbers. Prior to using the MFI and PSQI, the 
researcher contacted the developers of the instruments to ask for permission to use their 
instrument. Written permission to use the MFI was received from Dr. Smets (Appendix I). 
Similarly, written permission to use the PSQI was received from Dr. Buysse (Appendix J). The 
HADS was purchased online from GL Assessment which holds the copyright for the instrument. 
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 4.5 Instruments 
4.5.1 Fatigue  
 The MFI was used to measure subjective fatigue (Appendix K). The MFI was distributed 
to the participants by the researcher during the pulmonary rehabilitation sessions. The MFI has a 
total of 20 items, where the five subscales, each with four items, measure various dimensions of 
fatigue including: general fatigue, physical fatigue, reduced activity, reduced motivation, and 
mental fatigue. Participants rate their fatigue experienced during the past few days. Each item is 
rated on a scale from 1 to 5. A value of one indicated ‘yes, that is true’ and a value of five 
indicated ‘no, that is not true.’ When scoring, some of the items need to be recoded in reverse 
according to the scoring instructions. A total score is calculated for each subscale by adding the 
scores of the items in each subscale. Scores can range between 4 and 20, where a higher score 
indicated more fatigue. Smets et al. (1995) noted that calculating an overall score of the 20 items 
was not recommended. The data collected from the MFI was ordinal-level data, and relate to the 
four dimensions of fatigue that were examined in this study: emotional, behavioural, cognitive, 
and physical.  
 As discussed in the review of the literature, the MFI has been found to be a valid and 
reliable instrument for measuring fatigue. The MFI has good internal consistency (Gentile, 
Delaroziere, Sambuc, & San Marco, 2003; Hagelin, Wendstrom, Runesdotter, & Furst, 2007; 
Smets et al., 1995). The MFI has also been found to have good construct validity and convergent 
validity (Gentile et al.; Hagelin et al.; Smets et al., 1995; Smets, Garssen, Cull, & de Haes, 
1996). Two studies in the reviewed literature that used the MFI in examining subjective fatigue 
in patients with COPD were conducted by Breslin et al. (1998) and Breukink et al. (1998). Two 
more recent studies also used the MFI in individuals with lung conditions including cystic 
fibrosis (de Jong, van Aalderen, Kraan, Koeter, & van der Schans, 2001) and chronic lung 
disease (Oh, Kim, Lee, & Kim, 2004). 
The MFI was chosen as the instrument to measure fatigue because it has been used in the 
COPD population as well as various other clinical populations in examining various dimensions 
of fatigue. Many other multidimensional fatigue scales are lengthy; therefore, the MFI’s shorter 
length was feasible for individuals with COPD who often experience fatigue, and may have 
difficulty in completing a lengthy questionnaire. In addition, as demonstrated by the 
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 psychometric studies for the MFI, the instrument was accepted by the majority of the 
participants. 
4.5.2 Dyspnea 
  The MRC Dyspnea Scale was used as a measure of dyspnea (Appendix F). The most 
recent grades from the MRC Dyspnea Scale were found in participants’ pulmonary rehabilitation 
health records, and were recorded on a chart abstraction sheet by the researcher. Participants 
graded their dyspnea experienced with physical activity based on five descriptions on a scale 
between 1 and 5, and a higher score indicated more severe dyspnea (O’Donnell et al., 2008). The 
MRC Dyspnea Scale has been documented to be simple (Bestall et al., 1999; Fletcher, 1960), 
and standardized (Fletcher). The MRC Dyspnea Scale has been used in patients of various ages 
(de Jong et al., 1997), and in individuals who have various respiratory conditions including 
COPD (Darbee & Ohtake, 2006). The MRC Dyspnea Scale provides ordinal-level data.  
 As demonstrated in the review of the literature, the MRC Dyspnea Scale is a valid and 
reliable instrument to measure dyspnea in patients with respiratory conditions. The MRC 
Dyspnea Scale has been found to have good inter-rater reliability (Mahler & Wells, 1988), and 
good concurrent validity (de Jong et al., 1997; Guyatt et al.,1989; Hajiro et al., 2000; Lorenzi et 
al., 2004; Mahler & Wells). The MRC Dyspnea Scale was chosen as the method for measuring 
dyspnea because it was convenient and feasible.  
4.5.3 Activity Limitation 
 The 6MWT was used to measure activity limitation (Appendix F). The most current 
distances from the 6MWT were obtained from participants’ pulmonary rehabilitation health 
records, and were recorded in the chart abstraction sheet by the researcher. An individual walks 
quickly on a flat, hard surface for a six-minute period, and the total distance walked at the end of 
this period is measured (American Thoracic Society, 2002). The 6MWT has been used 
extensively in evaluating therapeutic interventions for pulmonary and cardiac disease and is 
repeated over time to measure change in distance (American Thoracic Society). It is still unclear 
as to what the best method is for measuring the change in an individual’s total distance from the 
6MWT (American Thoracic Society); however, the American Thoracic Society recommends that 
a change in distance be recorded as an absolute value until more research is available. 
Calculating the predicted distance using published studies from healthy individuals of a similar 
age group can help provide a reference for comparing the results, but there is great variability in 
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 studies due to the use of different methods (Enright, 2003). Healthy subjects’ distances obtained 
in the 6MWT have ranged between 400 and 700 metres (Enright). In one study, distances 
obtained in the 6MWT for 50 patients with mild to severe stable COPD was 437 ± 88.0 metres 
(Starobin et al., 2006). In a larger study, distances obtained in the 6MWT for 124 patients with 
moderate to severe COPD was 403.0 ± 81.6 metres (Carter et al., 2003). A low result is non-
specific and if the total distance from the 6MWT has reduced from the previous 6MWT, further 
investigation is required. Although the 6MWT is non-specific, it is “easy to administer, better 
tolerated, and more reflective of activities of daily living than the other walk tests” (Solway et 
al., 2001, p. 268). The data collected from the 6MWT was ratio-level data.  
From the review of the literature, several studies have found the 6MWT to have 
satisfactory construct and concurrent validity. The 6MWT was correlated with several lung 
diffusion tests and pulmonary function tests (Mak, Bugler, Roberts, & Spiro, 1993; Wijkstra et 
al., 1994), and the Borg scale (Wijksta et al., 1994).  
The 6MWT was chosen as the method for measuring activity limitation because it was 
convenient and feasible. In addition, it has been found to reflect ADLs more accurately than 
other walk tests (Solway et al., 2001).  
4.5.4 Depression and Anxiety 
  The Hospital Anxiety and Depression Scale (HADS) was used to measure anxiety and 
depression (Appendix L). The HADS was distributed to the participants by the researcher during 
the pulmonary rehabilitation sessions. The HADS measured how the participant felt during the 
past week. The scale is comprised of 14 items of which seven items measure depression and the 
remaining seven items measure anxiety. Items are rated on a scale between 0 and 3. The values, 
zero, one, two and three have various corresponding descriptors for the feelings described. These 
values, along with their corresponding descriptors, are reversed in some items. The values on 
individual items are added and scores can range between 0 and 21. A score between 8 and 10 in 
either the anxiety items or depression items indicated probable presence of clinical caseness. The 
data collected from the HADS was ordinal-level data.  
As indicated in the review of the literature, the HADS has been found to be a valid and 
reliable instrument for measuring anxiety and depression. The HADS has good internal 
consistency (Zigmond & Snaith, 1983), with a Cronbach’s alpha of 0.93 for the anxiety subscale, 
and 0.90 for the depression subscale (Moorey et al., 1991). In addition, good internal consistency 
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 has been found from the item-to-subscale reliability coefficients (Zigmond & Snaith). One study 
in the reviewed literature, conducted by Krishnasamy (1997, 2000) used the HADS. The HADS 
was used to screen for psychiatric morbidity while examining fatigue in advanced cancer. 
 The HADS was chosen as the instrument to measure depression and anxiety in this study 
because it has been validated in the chronic illness population. In addition, the HADS is shorter 
in length and easier to complete when compared to other depression and anxiety instruments. As 
mentioned earlier, a shorter instrument will likely be easier and less demanding for the COPD 
participants in this study who could be affected by fatigue. 
4.5.5. Sleep Quality 
  The PSQI was used to measure sleep quality (Appendix M). The PSQI was distributed to 
the participants by the researcher during the pulmonary rehabilitation sessions. The PSQI 
measures the participant’s sleep quality during the past month. The scale is comprised of 19 
items. There are five additional items that are assessed by the participant’s bed partner. These 
five items are not used to determine the overall score. Since these five items are not used to 
determine the overall score, they were not distributed to the participants. The 19 items are 
divided into seven components: sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each of these 
19 items are rated on a scale between 0 and 3. A value of zero indicates no difficulty and a value 
of three indicates severe difficulty. The values on individual items are added and scores can 
range between 0 and 21. A higher score indicates worse sleep quality. The data collected from 
the PSQI was ordinal-level data. The PSQI has been documented to be easy to use and 
understand (Buysse et al., 1989).  
As discussed in the review of the literature, the PSQI has been found to be a valid and 
reliable instrument for measuring sleep quality. The PSQI has high internal consistency 
(Carpenter & Andrykowski, 1998, Buysse et al., 1989). The PSQI has high test-retest reliability 
and concurrent validity (Buysse et al.), as well as good construct validity (Carpenter & 
Andrykowski). Two studies in the reviewed literature used the PSQI to study sleep quality in 
individuals with COPD (Kapella et al., 2006; Reishtein, 2005).  
The PSQI was chosen as the instrument for measuring sleep quality because it was the 
most appropriate in assessing sleep quality. Other instruments, in the form of questionnaires, 
examine sleepiness at a given point in time which was not applicable to this study. 
 29
 4.5.6 Heart Rate 
  The data on heart rate was gathered from each participant’s pulmonary rehabilitation 
health record and recorded on a chart abstraction sheet (Appendix F) by the researcher. Heart 
rate was recorded as the number of heart beats per minute. 
4.5.7 Oxygen Saturation  
 The data on oxygen saturation was gathered from each participant’s pulmonary 
rehabilitation health record and recorded on a chart abstraction sheet (Appendix F) by the 
researcher. Oxygen saturation was recorded as a percentage of the maximal binding capacity. 
4.5.8 Extraneous Variables  
 The extraneous variables including: smoking status, amount of pulmonary rehabilitation 
received, co-morbidities, and supplemental oxygen use were gathered from each participant’s 
pulmonary rehabilitation health record and recorded on a chart abstraction sheet (Appendix F) by 
the researcher. Smoking status was recorded as either currently smokes, non-smoker, or ex-
smoker. Amount of pulmonary rehabilitation received was determined by using the date of the 
first day a participant began attending pulmonary rehabilitation. This date was recorded by day, 
month, and year. Co-morbidities was recorded by the number of co-morbidities a participant had. 
Supplemental oxygen use was recorded as either uses supplemental oxygen, or does not use 
supplemental oxygen.  
The remaining extraneous variables: age and gender, was obtained from the demographic 
form (Appendix E) which each participant completed. To determine age, each participant 
recorded the number of years from his or her date of birth. To determine sex, each participant 
recorded how he or she referred to himself or herself as either male or female. 
4.6 Procedure 
 The researcher had a meeting with the coordinator and the manager of the Saskatoon 
Health Region’s pulmonary rehabilitation program to discuss the details of the study before 
applying for ethical approval. Once ethical approval was received from the University of 
Saskatchewan Behavioural Ethics Board and operational approval was obtained from the 
Saskatoon Health Region, the pulmonary rehabilitation coordinator was made aware that 
participant recruitment would begin. Throughout the process of recruiting participants, the 
researcher was present during most of the pulmonary rehabilitation sessions at both locations for 
a period of two months. The coordinator and pulmonary rehabilitation staff briefly introduced the 
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 study to the individuals during the sessions, distributed brochures, and directed interested 
individuals to the researcher. The researcher also distributed brochures to individuals, explained 
the study and answered questions. The researcher met with each interested participant 
individually, recorded the participant’s name and assigned him or her an unique identification 
number on the Master List of Participants and Associating Unique Identification Numbers form, 
reviewed the consent form, ensured that two copies of the consent form were signed, and offered 
him or her the opportunity to receive the results from the study by completing the Request for 
Results From Research Study Form. Each participant was then given a demographic form and 
was asked to complete it. The researcher read the instructions in each questionnaire out loud to 
the participant, answered any questions he or she had, and the participants proceeded with 
completing the questionnaires. The MFI was completed first, followed by the HADS, and lastly 
the PSQI. Data on dyspnea, activity limitation, heart rate, oxygen saturation, smoking status, 
amount of pulmonary rehabilitation received, co-morbidities, current medications, PFTs, and 
supplemental oxygen use were collected from each participant’s pulmonary rehabilitation health 
record, and recorded on a chart abstraction sheet.  
 A codebook was developed by the researcher for each variable in each instrument, the 
demographic form, and the chart abstraction sheet before data analysis was initiated to help 
manage data and facilitate data analysis. The researcher coded the data according to the 
codebook. 
4.7 Data Analysis 
 The primary research questions addressed in this thesis were: (a) what proportion of the 
individuals with COPD receiving pulmonary rehabilitation experienced emotional, behavioural, 
cognitive, and physical dimensions of subjective fatigue, and (b) what are the relationships 
between each of the four dimensions of subjective fatigue and various symptoms (dyspnea, 
depression, anxiety, sleep quality, activity limitation, heart rate, and oxygen saturation) in these 
individuals? The secondary research questions addressed were: (a) how do men and women 
compare on the four dimensions of subjective fatigue, (b) how do individuals who use 
supplemental oxygen and those who do not use supplemental oxygen compare on the four 
dimensions of subjective fatigue, (c) how do ex-smokers, non-smokers, and those who currently 
smoke compare on the four dimensions of subjective fatigue, (d) how do the individuals’ severity 
of dyspnea according to the MRC Dyspnea Scale grades compare on the four dimensions of 
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 subjective fatigue, and (e) what are the relationships between the four dimensions of fatigue and 
age, the number of co-morbidities, and the amount of pulmonary rehabilitation received?  
 Data from the questionnaires and chart abstraction sheets were entered into SPSS 16.0, 
and recoded when required according to the questionnaires’ scoring instructions. For the 
descriptive analysis, frequencies and percentages were calculated for most variables. For ordinal 
and ratio variables, measures of central tendencies and dispersion were determined.  
 T-tests or one-way ANOVAs (analysis of variance) were performed to examine 
significant differences between groups. For two sets of sample data, a t-test was used, and for 
three or more sets of sample data, a one-way ANOVA was used. For the ordinal and ratio 
variables, Spearman’s rho correlation coefficients were calculated. All variables, with the 
exception of the amount of pulmonary rehabilitation received which was slightly leptokurtic, met 
acceptable levels of normality.  
 T-test for independent samples were calculated to determine whether significant 
differences existed in the means between men and women, and between having used and not 
having used supplemental oxygen for each of the MFI subscales. A one-way ANOVA was used 
to determine whether significant differences existed among the means of non-smokers, ex-
smokers, and those who currently smoke, and among the different grades obtained in the MRC 
Dyspnea Scale for each of the MFI subscales. Spearman’s rho correlation coefficients were 
calculated to explore whether significant relationships existed between each of the MFI subscales 
and dyspnea, anxiety, depression, activity limitation, sleep quality, heart rate, oxygen saturation, 
age, number of co-morbidities, and amount of pulmonary rehabilitation received. For all 
statistical tests, an alpha of 0.05 indicated statistical significance.   
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CHAPTER V 
Results 
5.1 Participation Rate 
 Forty-five participants were approached by the researcher or pulmonary rehabilitation 
staff during attendance at the pulmonary rehabilitation sessions between October 2008 and 
December 2008, and a total of 42 participants agreed to participate in the study (participation rate 
= 93.3%). Of these participants, 13 attended pulmonary rehabilitation at the Confederation Mall 
location, and 29 attended pulmonary rehabilitation at the Saskatoon Field House location. All 42 
participants completed the questionnaires, and the researcher was able to assess all their health 
records at the location where they participated in pulmonary rehabilitation. 
5.2 Characteristics of the Sample 
 The characteristics of the participants in the sample can be referred to in Tables 5.1 and 
5.2. The sample was 17 (40.5%) male, and 25 (59.5%) female. The participants’ ages ranged 
between 56 and 87 years, and the mean was 72.9 years (SD = ±6.5). Data on co-morbidities, 
smoking status, and supplemental oxygen were collected by the pulmonary rehabilitation staff 
during the preliminary assessment period when they met participants individually for the first 
time. The mean number of co-morbidities was 2.6 (Mdn = 3, Md = 1, SD = ±1.4) and 52.4% had 
three or more co-morbidities. There were 33 (78.6%) ex-smokers, 7 (16.7%) current smokers, 
and 2 (4.8%) non-smokers. There were 11 (26.2%) participants who used supplemental oxygen, 
and 31 (73.8%) who did not use supplemental oxygen. The mean number of months of 
pulmonary rehabilitation received was 25 (R = 0 – 75, SD = ±26). The most recent MRC 
Dyspnea Scale grades were obtained from 30 of the participants’ health records. MRC Dyspnea 
Scale grades had been recorded within the last three months in 43.3% of the participants, within 
the last 3 to 6 months in 16.7% of the participants, within the last 6 to 12 months in 10.0% of the 
participants, and over 12 months ago in 30.0% of the participants. The mean MRC Dyspnea 
Scale grade was 2.6 (Md = 3, R = 1 – 4). The most recent 6MWT distances were obtained from 
41 of the participants’ health records. The mean distance was 356 metres (SD = ±90), and ranged 
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 between 126 metres and 552 metres. The most recent oxygen saturation and heart rate for 
walking were collected from all participants’ health records. The mean oxygen saturation was 
92.6% (SD = ±4.1), and the mean heart rate reading was 102 beats per minute (SD = ±14.4). The 
most recent PFTs were available in 14 health records. The mean FEV1 (% predicted) was 47.8 
(SD = ±16.3), the mean FVC (% predicted) was 78.9 (SD = ±18.1), and the mean FEV1/FVC was 
0.68 (SD = ±0.13). The COPD medications which participants used were gathered from the most 
recent time of assessment. The number of participants and the medications they used were as 
follows: 22 (52.4%) used Salbutamol, 1 (2.4%) used Formoterol, 2 (4.8%) used Salmeterol, 9 
(21.4%) used Ipatropium, 18 (42.9%) used Tiotropium, 4 (9.5%) used the Salbutamol and 
Ipatropium combination, 10 (23.8%) used the Fluticasone and Salmeterol combination, 6 
(14.3%) used the Budesonide and Formoterol combination, 1 (2.4%) used Fluticasone, 1 (2.4) 
used Budesonide, and 1 (2.4%) used Beclomethasone.  
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Table 5.1. Participants’ Demographic Characteristics 
 
 
Characteristics   n  M  SD  Frequency Percent  
     Age    42  72.9 years ±6.5                                                 
  
     Sex    42 
          Male         17  40.5 
          Female         25  59.5 
  
     Smoking status    42 
          Ex-smokers         33  78.6 
          Current smokers        7  16.7 
          Non-smokers         2  4.8 
 
n = number of participants 
M = mean 
SD = standard deviation 
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Table 5.2. Participants’ Health Status and Pharmacologic Characteristics 
 
 
Characteristics        n          M                         SD              Frequency  Percent 
     MRC Dyspnea Scale       30         2.6                                   
      
     Co-morbidities       42         2.6                        ±1.4    
      
     Amount of pulmonary       42         25 months              ±26 
     rehabilitation received     
  
     6MWT       41                 356 metres        ±90 
 
     Oxygen saturation      42         92.6%        ±4.1 
    
     Heart rate       42         102 beats/minute    ±14.4 
       
     Pulmonary function tests       14 
          FEV1 (% predicted)            47.8          ±16.3 
          FVC (% predicted)            78.9          ±18.1 
          FEV1/FVC                     0.68          ±0.13 
 
     Supplemental oxygen use      42      
          Used supplemental oxygen       11  26.2 
          Did not use supplemental oxygen       31  73.8 
 
     Medications        42 
          SABA         22  52.4 
               Salbutamol        22  52.4 
  
          LABA         3  7.2 
               Formoterol        1  2.4 
               Salmeterol        2  4.8 
  
          Anticholinergic        27  64.3 
               Ipatropium        9  21.4 
               Tiotropium        18  42.9 
  
          SABA and anticholinergic       4  9.5 
               Salbutamol and Ipatropium combination     4  9.5 
                   
          LABA and corticosteroid       16  38.1 
               Fluticasone and Salmeterol combination      10  23.8 
               Budesonide and Formoterol combination     6  14.3 
  
          Corticosteroid        3  7.2 
               Fluticasone        1  2.4 
               Budesonide        1  2.4 
               Beclomethasone        1  2.4 
 
n = number of participants 
M = mean 
SD = standard deviation 
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 5.3 Questionnaires 
 The results of the scores obtained in the MFI, HADS, and PSQI are shown in Table 5.3. 
5.3.1 MFI  
 The MFI has 20 items which measure all four dimensions of fatigue (physical, 
behavioural, cognitive, and emotional) from the conceptual framework which guided this study. 
Scores between 4 and 20 are possible for each of the MFI subscales, where higher scores indicate 
more fatigue. According to Piper (2003), the physical or sensory dimension, also known as 
general, physical, or somatic fatigue, includes signs and symptoms of fatigue and their 
intensities, which can be localized to a specific part of the body, or generalized over the whole 
body. Two MFI subscales, general fatigue and physical fatigue, measure the physical dimension 
of fatigue. The mean score was 11.1 (SD = ±2.3, R = 6 – 17) for general fatigue, and 13.5 (SD = 
±2.2, R = 8 – 18) for physical fatigue. The behavioural dimension includes signs and symptoms 
that reflect changes in physical performance, ADLs, or the amount of effort needed to perform 
physically (Piper, 2003). The MFI subscale reduced activity, measures the behavioural 
dimension of fatigue. The mean score for reduced activity was 13.0 (SD = ±2.3, R = 8 – 19). The 
emotional, also known as affective or psychologic dimension, consists of emotional effects of 
fatigue which includes reduced motivation (Piper, 2003). The MFI subscale reduced motivation 
measures the emotional dimension of fatigue. The mean score for reduced motivation was 12.8 
(SD = ±2.3, R = 6 – 18). Piper (2003) outlined that the cognitive or mental dimension includes 
indicators of changes in thought or concentration. The MFI subscale mental fatigue assesses the 
cognitive dimension of fatigue. The mean was score was 11.2 (SD = ±1.8, R = 7 – 16) for mental 
fatigue.  
 Participants’ scores on the five MFI subscales from most fatigue to least fatigue were: 
physical fatigue, reduced activity, reduced motivation, mental fatigue, and general fatigue. A 
higher score on the MFI indicates more fatigue; however, the MFI does not have specific 
guidelines to differentiate the severity of fatigue. For the purpose of differentiating the severity 
of fatigue to help make the findings in this present study more meaningful, the researcher 
decided that a score between 4 and 9 indicated mild fatigue, a score between 10 and 14 indicated 
moderate fatigue, and a score between 15 and 20 indicated severe fatigue. Decisions on these 
score ranges were guided by percentiles and measures of central tendencies. The mean subscales 
scores at the 50th percentile and the overall mean score on all subscales were approximately 12. 
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 Therefore, a mean of 12 formed the middle score for the moderate fatigue score range, and the 
mild and severe fatigue score ranges were approximately equally divided into the two remaining 
severity categories. The majority of the participants reported moderate levels of fatigue on all 
MFI subscales: general fatigue (69.0%), physical fatigue (61.9%), reduced activity (71.4%), 
reduced motivation (64.2%), and mental fatigue (81.0%). Most of the participants experienced 
moderate levels of fatigue for all dimensions including: fatigue affecting general functioning and 
physical sensations related to fatigue (physical dimension), reduced activity as a possible 
consequence of fatigue (behavioural dimension), reduced motivation (emotional dimension), and 
cognitive symptoms such as difficulty concentrating (cognitive dimension). The percentage of 
the sample that experienced mild, moderate, and severe levels of fatigue on the MFI subscales 
and associated fatigue dimensions are displayed in Table 5.4. 
5.3.2 HADS 
  The HADS is comprised of two subscales, anxiety and depression. There are seven items 
in the anxiety subscale which assess anxiety, and seven items in the depression subscale which 
assess depression. A higher score indicates more anxiety or depression, and a score of eight or 
higher indicates probable clinical presence of anxiety or depression. Possible scores for each 
subscale range between 0 and 21. The mean score on the HADS anxiety subscale was 7.0 (SD = 
±3.6, R = 0 – 15), and on the HADS depression subscale was 5.3 (SD = ±2.9, R = 1 – 15). For the 
anxiety and depression subscales, 42.9% and 21.4% of the participants, respectively, scored an 
eight or higher. 
5.3.3 PSQI  
 The 19 items in the PSQI used in this study measured an individual’s sleep quality by 
assessing seven components (sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction). Possible 
scores range between 0 and 21, where a higher score indicates greater sleep difficulty in all 
components. The mean score on the PSQI was 7.1 (SD = ±4.1, R = 1 – 15).  
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Table 5.3. Results from Questionnaires 
 
Questionnaire     n R  M  SD  
 MFIa    42 
  General fatigue   6-17  11.1  ±2.3   
  Physical fatigue   8-18  13.5  ±2.2 
  Reduced activity   8-19  13.0  ±2.3 
  Reduced motivation  6-18  12.8  ±2.3 
  Mental fatigue   7-16  11.2  ±1.8 
 
 HADSb    42 
  Anxiety    0-15  7.0  ±3.6    
  Depression   1-15  5.3  ±2.9 
 
 PSQIc    42 1-15  7.1  ±4.1 
 
a Scores can range between 4 and 20 for each subscale. A higher score indicates more fatigue. 
b Scores can range between 0 and 21 for each subscale. A score between 0 and 7 is normal. A score greater than or equal to 8 
indicates probable presence of clinical anxiety or depression. 
c Scores can range between 0 and 21. A higher score indicates greater sleep difficulty in all components. 
 
n = number of participants 
R = range 
M = mean 
SD = standard deviation 
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Table 5.4. Comparison of Mild, Moderate, and Severe Fatigue Levels on the MFI Subscales and Associated Fatigue Dimensions 
 
 
    Mild    Moderate    Severe          
 
General Fatigue   21.5%    69.0%    9.6%            
(Physical Dimension) 
        
Physical Fatigue   4.8%    61.9%    33.4% 
(Physical Dimension) 
     
Reduced Activity             4.8%    71.4%    23.9% 
(Behavioural Dimension) 
      
Reduced Motivation  11.9%    64.2%    23.8% 
(Emotional Dimension) 
 
Mental Fatigue    16.6%    81.0%    2.4% 
(Cognitive Dimension)        
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 5.4 Comparisons and Correlations 
 Comparison of men and women, the use of supplemental oxygen, smoking status, and 
MRC Dyspnea Scale grades on the MFI subscales are displayed in Tables 5.5 – 5.8. Correlations 
between the MFI subscales and age, number of co-morbidities and amount of pulmonary 
rehabilitation received can be referred to in Table 5.9. Correlations among the MFI subscales and 
associated fatigue dimensions, physiologic, psychologic, and situational influencing factors 
(dyspnea, depression, anxiety, sleep quality, activity limitation, heart rate, and oxygen saturation) 
are shown in Table 5.10. 
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Table 5.5. Comparison of Men and Women on the MFI Subscales  
 
 
                             Men                 Women 
________________________________________________________________________________________________________ 
              n              M               SD            n              M               SD  t-test p value  
            (2-tailed) 
 
General Fatigue           17             11.0            ±2.2         25            11.2            ±2.5  -0.32 0.75 
        
Physical Fatigue           17             14.1            ±2.0        25            13.2            ±2.4  1.37 0.18 
     
Reduced Activity           17             12.3            ±2.3        25            13.4            ±2.2  -1.53 0.13 
      
Reduced Motivation         17            12.4            ±3.0       25            13.1    ± 2.4   -0.81 0.42 
     
Mental Fatigue           17            11.2            ±1.0             25            11.2     ±2.2  0.07 0.94 
 
n = number of participants 
M = mean 
SD = standard deviation 
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Table 5.6. Comparison of the Use of Supplemental Oxygen on the MFI Subscales 
 
 
           Uses Supplemental Oxygen         Does Not Use Supplemental Oxygen 
________________________________________________________________________________________________________ 
             n              M              SD            n              M               SD  t-test p value  
            (2-tailed) 
          
General Fatigue           11           11.4           ±2.2         31            11.1            ±2.4  0.36 0.72 
           
Physical Fatigue           11            13.0           ±1.9        31            13.7            ±2.4  -0.94 0.35 
     
Reduced Activity           11            14.0           ±2.0        31            12.6            ±2.3  1.72 0.09 
      
Reduced Motivation         11           13.2           ±2.1       31            12.7     ±2.8   0.55 0.59 
     
Mental Fatigue           11           10.9           ±1.4             31            11.3     ±1.9  -0.66 0.51 
 
n = number of participants 
M = mean 
SD = standard deviation 
  
 
 
 
 
 
 
 
 
 
Table 5.7. Comparison of Smoking Status with the MFI Subscales 
 
 
                  Non-Smokers                     Current Smokers                 Ex-Smokers               Total 
________________________________________________________________________________________________________________________________________________ 
           n           M            SD                      n           M             SD                     n            M             SD                     n            M             SD F-test p value  
             
General Fatigue          2          11.0         ±1.4                     7          12.0          ±1.5        33         11.0           ±2.5                   42          11.1          ±2.3 0.55 0.58 
       
44 Physical Fatigue          2          14.0         ±2.8                     7          13.4          ±2.5        33         13.5           ±2.2                   42          13.5          ±2.2 0.05 0.96                       
Reduced Activity          2          12.0         ±1.4                     7          12.6          ±2.1        33         13.2           ±2.4                   42          13.0          ±2.3 0.37 0.70 
          
Reduced Motivation        2          10.0         ±2.8                     7          15.6          ±2.4        33         13.0           ±2.6                   42          12.8          ±2.6 1.32 0.28 
     
Mental Fatigue          2          12.0         ±0.0                     7          11.4          ±1.8        33         11.1           ±1.8                   42          11.2          ±1.8 0.28 0.76  
 
n = number of participants 
M = mean 
SD = standard deviation 
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Table 5.8. Comparison of MRC Dyspnea Scale Grades on the MFI Subscales 
 
 
                      1                               2                           3                       4                                      Total 
________________________________________________________________________________________________________________________________________________ 
           n        M        SD               n         M         SD               n         M         SD               n         M         SD               n        M         SD  F-test p value  
             
General Fatigue          2       13.0     ±1.4            10        10.9      ±3.3           16       10.8       ±1.3            2        11.0       ±2.8            30      11.0      ±2.2 0.58 0.64    
      
Physical Fatigue          2       15.5     ±3.5  10        13.6      ±2.5           16       12.9       ±1.9            2        12.0       ±1.4            30      13.3      ±2.2 1.07 0.38              
                       
Reduced Activity          2       13.0     ±2.8            10        12.6      ±3.0           16       12.9       ±1.5            2        13.5       ±2.1            30      12.9      ±2.1 0.11 0.95 
           
Reduced Motivation        2       14.0     ±5.7            10        12.2      ±3.2           16       12.4       ±2.2            2        12.0       ±0.0            30      12.4      ±2.6 0.26 0.85 
     
Mental Fatigue          2       10.5     ±2.1            10        11.4      ±2.7           16       11.0       ±1.5            2        11.5       ±0.7            30      11.1      ±2.0  0.20 0.90 
 
 
 
n = number of participants 
M = mean 
SD = standard deviation 
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Table 5.9. Correlations between the MFI Subscales and Age, Number of Co-morbidities and Amount of Pulmonary 
Rehabilitation Received  
 
 
MFI Subscales  n  Age  Number of   Amount of Pulmonary 
       Co-morbidities  Rehabilitation Received 
General Fatigue  42  -0.01  0.20   -0.02 
 
Physical Fatigue  42  0.11  0.17   0.06 
 
Reduced Activity  42  0.43**  0.16   0.08 
 
Reduced Motivation 42  0.31*  0.12   0.22  
 
Mental Fatigue  42  -0.09  0.05   -0.03 
 
n = number of participants 
 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
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Table 5.10. Correlations among the MFI Subscales and Associated Fatigue Dimensions, Physiologic, Psychologic, and 
Situational Influencing Factors 
 
 
               Physiologic                Psychologic        Situational 
________________________________________________________________________________________________________ 
MFI Subscales  Dyspnea     Activity      Heart Rate     Oxygen     Depression     Anxiety      Sleep Quality  
        Limitation                 Saturation 
General Fatigue  -0.11    -0.17        0.02             -0.10     0.00            0.23      0.04 
(Physical Dimension) 
 
Physical Fatigue  -0.33    -0.11       -0.21             0.24     -0.22            -0.23      -0.19 
(Physical Dimension) 
 
Reduced Activity  0.12    -0.25       -0.08             -0.11     -0.29            -0.28      -0.07 
(Behavioural Dimension) 
 
Reduced Motivation -0.09    -0.07       0.09             -0.02     -0.20            -0.47**      -0.05 
(Emotional Dimension) 
 
Mental Fatigue  -0.04    0.11       -0.04             0.05     -0.30            -0.22      0.16 
(Cognitive Dimension) 
 
** Correlation is significant at the 0.01 level (2-tailed). 
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  Men and women did not significantly differ in their MFI subscales scores. Those who 
used supplemental and those who did not use supplemental oxygen did not significantly differ in 
their MFI subscale scores. Ex-smokers, currently smokers, and non-smokers did not significantly 
differ in their MFI subscales scores. There were no significant differences in the MFI subscales 
scores among the different MRC Dyspnea Scale grades. Age positively correlated with two of 
the MFI subscales, reduced activity [ρ = 0.43, p < 0.01] and reduced motivation [ρ = 0.31, p < 
0.05], but did not correlate with the remaining MFI subscales scores. The number of co-
morbidities and the amount of pulmonary rehabilitation received did not correlate with the MFI 
subscales scores. 
 The MRC Dyspnea Scale grades, HADS depression subscale scores, PSQI sleep quality 
scores, 6MWT distances, heart rate, and oxygen saturation readings did not correlate with any of 
the MFI subscales scores. The HADS anxiety subscale negatively correlated with reduced 
motivation [ρ = -0.47, p < 0.01], but did not correlate with the remaining MFI subscales scores. 
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CHAPTER VI 
Discussion 
 Fatigue is a common and distressing symptom in individuals with COPD (Kinsmen et al., 
1983, Theander & Unosson, 2004). It has a significant negative impact on quality of life, 
including physical, psychological, social, and cognitive functioning (Theander & Unosson). 
Pulmonary rehabilitation is strongly encouraged in individuals with COPD to help improve their 
quality of life (O’Donnell et al., 2008) among other benefits such as reducing fatigue (Lacasse et  
al., 2004). 
 The following summarizes the results and provides answers to the primary and secondary 
research questions.  
6.1 Primary Research Questions 
• 1. What proportion of the individuals with COPD receiving pulmonary rehabilitation 
experienced emotional, behavioural, cognitive, and physical dimensions of subjective 
fatigue? The majority of the participants experienced moderate levels of subjective 
fatigue in all four dimensions. Moderate to severe levels of physical fatigue were 
experienced in 95.3% of the participants. 
• 2. What are the relationships between each of the four dimensions of subjective fatigue 
and various symptoms (dyspnea, depression, anxiety, sleep quality, activity limitation, 
heart rate, and oxygen saturation) in these individuals? The only significant finding was a 
negative relationship between anxiety and emotional fatigue (reduced motivation). There 
were no significant relationships between any of the fatigue dimensions and the other 
influencing factors: sleep quality, activity limitation, dyspnea, oxygen saturation, heart 
rate, and depression. 
6.2 Secondary Research Questions 
• 1. How do men and women compare on the four dimensions of subjective fatigue? Men 
and women did not significantly differ in the four dimensions of subjective fatigue. 
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 • 2. How do individuals who use supplemental oxygen and those who do not use 
supplemental oxygen compare on the four dimensions of subjective fatigue? Those who 
used supplemental oxygen and those who did not use supplemental oxygen did not 
significantly differ in the four dimensions of subjective fatigue. 
• 3. How do ex-smokers, non-smokers, and those who currently smoke compare on the 
four dimensions of subjective fatigue? Ex-smokers, non-smokers, and those who 
currently smoke did not significantly differ in the four dimensions of subjective fatigue. 
• 4. How do the individuals’ severity of dyspnea according to the MRC Dyspnea Scale 
grades compare on the four dimensions of subjective fatigue? There were no significant 
differences in the four dimensions of subjective fatigue among the different MRC 
Dyspnea Scale grades. 
• 5. What are the relationships between the four dimensions of fatigue and age, the number 
of co-morbidities, and the amount of pulmonary rehabilitation received? There was a 
significant positive relationship between age and two dimensions: emotional fatigue 
(reduced motivation) and behavioural fatigue (reduced activity). There were no 
significant relationships between the four dimensions of fatigue and the number of co-
morbidities and the amount of pulmonary rehabilitation received. 
6.3 Participation Rate 
 The participation rate in this study was high, indicating that participants in the pulmonary 
rehabilitation program showed great interest in this study. Participants found the questionnaires 
easy and quick to complete. Participants typically completed the questionnaires in 10 to 15 
minutes. 
6.4 Severity of COPD 
 Based on the pulmonary function tests of 14 participants that were available in the health 
records, a mean FEV1/FVC of less than 0.7 confirmed a diagnosis of COPD, and a mean FEV1 of 
47.8% of the predicted value for the participants’ age, size and sex, indicated that they had 
severe COPD (O’Donnell et al., 2008).   
6.5 Sex 
 More women (59.5%) than men (40.5%) participated in this study. The gender 
distribution was different than the population from which the sample was drawn. According to 
the information provided by the pulmonary rehabilitation coordinator, there are slightly more 
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 men (54.3%) than women (45.7%) with COPD in the pulmonary rehabilitation program. Similar 
to this present study, more women than men participated in a few COPD studies (Janson-Bjerklie 
et al., 1986; Woo, 2000a; Woo, 2000b). However, more men than women participated in 11 
COPD studies (Breslin et al., 1998; Breukink et al., 1998; Carter et al., 2006; Dowson et al., 
2001; Gift & Shepard, 1999; Kapella et al., 2006; Kinsmen et al., 1983; Oh et al., 2004; 
Reishtein, 2005; Small & Graydon, 1992; Starobin et al., 2006). Some possible explanations as 
to why more women than men participated in this study include gender differences in health 
beliefs and health seeking behaviour. For example, women may be more aware and distressed by 
their symptoms, and are more willing to seek health care services. In addition, it may be more 
socially acceptable for women to report symptoms than for men to do so. 
 There were no significant differences between men and women in this study for any of 
the MFI subscales, which demonstrated that men and women did not significantly differ in the 
various dimensions of fatigue they experienced. This finding was also similar to other COPD 
studies (Gift & Shepard, 1999; Kapella et al, 2006; Oh et al., 2004). Although the results from 
this present study indicate that there were no differences between men and women in the fatigue 
they experienced, symptoms such as dyspnea, anxiety, and depression have been reported to be 
higher in women than in men (Gift & Shepard, 1999), which may affect the overall fatigue levels 
experienced. 
6.6 Age 
 Information to estimate the mean age of the COPD population in the pulmonary 
rehabilitation program was provided by the pulmonary rehabilitation coordinator. The estimated 
mean age of the individuals in this population was 66 years, and when compared to the 
participants in this present study with a mean age of 72.9 years, the participants in this study 
were slightly older. In addition, the participants were slightly older in this present study than 
several COPD studies where the reported means ranged between 62 and 69.9 years (Breslin et 
al., 1998; Breukink et al., 1998; Carter et al., 2006; Dowson et al., 2001; Gift & Shepard, 1999; 
Janson-Bjerklie et al., 1986; Kapella et al., 2006; Kinsmen et al., 1983; Oh et al., 2004; 
Reishtein, 2005; Small & Graydon, 1992; Starobin et al., 2006; Woo, 2000a; Woo, 2000b). With 
older participants in the study, a positive relationship between age and fatigue was anticipated. 
As individuals get older, they may experience more fatigue because of their decrease in physical 
strength associated with aging. 
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  There was a significant positive relationship between age and two of the MFI subscales, 
reduced activity and reduced motivation. The reduced activity and reduced motivation subscales 
measure the behavioural and emotional dimensions of fatigue, respectively; therefore, there was 
a significant positive relationship between age and behavioural fatigue, and between age and 
emotional fatigue. One possible explanation for this finding was that with increasing age and the 
natural process of aging, participants were not physically as strong as when they were younger, 
and needed to exert more effort to perform physically. This decrease in physical strength may 
have negatively impacted their ability to carry out ADLs. A reduction in the participants’ 
motivation to start activities may have been a result of the decline in physical strength that comes 
with increasing age. Previous studies found that age was not significantly related to the amount 
of fatigue experienced (Reishtein, 2005; Woo, 2000b). These studies examined the amount of 
fatigue experienced, and did not examine different dimensions of fatigue. 
6.7 Fatigue 
 The results from this present study indicate that the majority of participants experienced 
moderate levels of general fatigue (69.0%), physical fatigue (61.9%), reduced activity (71.4%), 
reduced motivation (64.2%), and mental fatigue (81.0%) based on the MFI subscales. This meant 
that most of the participants experienced moderate levels of fatigue for all dimensions (physical, 
behavioural, emotional, and cognitive). In addition, moderate to severe levels of physical fatigue 
were experienced in 95.3% of the participants. The means in the MFI subscales ranged between 
11.1 and 13.5, which were expected based on several other studies which used the MFI with 
individuals who had moderate to severe COPD. The means on the MFI subscales in these studies 
ranged between 10.5 and 13.0 (Oh et al., 2004), between 9.8 and 14.5 (Breslin et al., 1998), and 
between 9.7 and 14.6 (Breukink et al., 1998). 
 Although a common conceptualization of the physical fatigue dimension includes general 
fatigue according to Piper (2003), the results in this study suggested that physical and general 
dimensions of fatigue were separate in these participants because the scores were highest on the 
physical fatigue subscale, and lowest on the general fatigue subscale. The physical sensations of 
the fatigue they experienced were not only more severe, but perhaps also different from the 
fatigue they experienced which affected their overall functioning. It may be possible that the 
participants’ physical sensations of the fatigue they experienced may not have affected how they 
perceived their general functioning. The conceptual framework used in this study worked well 
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 for conceptualizing emotional, behavioural and cognitive fatigue dimension. However, the 
conceptual framework which included the common conceptualization of general fatigue as part 
of physical fatigue, did not work well in conceptualizing the physical dimension because the 
results from this study suggested a distinction between the physical and general fatigue 
dimensions. 
 Similar results where physical fatigue was also highest, followed by reduced activity was 
noted by Breslin et al. (1998) in pulmonary rehabilitation participants, and by Oh et al. (2004). 
Participants scored lowest in general fatigue in this present study, which was different from three 
other COPD studies where mental fatigue was lowest (Breslin et al., 1998; Breukink et al., 1998, 
Oh et al., 2004). In one cancer study, mental fatigue was also lowest, but general fatigue was 
highest (Smets et al., 1996). In other COPD studies which used other fatigue instruments, results 
showed that subjects experienced moderate to high levels of fatigue (Gift & Shepard, 1999; 
Kapella et al., 2006; Woo, 2000a; Woo, 2000b). The moderate amounts of fatigue experienced 
by the participants in this present study and in the study conducted by Breslin et al. (1998) on 
individuals with COPD attending pulmonary rehabilitation may suggest that many individuals 
attending pulmonary rehabilitation experience moderate amounts of fatigue. Whether or not 
pulmonary rehabilitation is effective in reducing the fatigue was not examined in this study; 
however, it would be worth examining in future studies.  
6.8 Physiologic Factors 
 Moderate amounts of dyspnea were reported in 53.3% of the participants, where a mode 
of three was calculated from the MRC Dyspnea Scale grades. Similar to this present study, one 
previous work using the MRC Dyspnea Scale found that pulmonary rehabilitation participants 
with COPD experienced moderate to severe dyspnea (Bestall et al., 1999). Relatively high 
amounts of dyspnea were reported by outpatient participants with COPD in two other studies; 
however, a different instrument was used to measure dyspnea (Woo 2000a, Woo, 2000b).  
 It was anticipated that a positive relationship between dyspnea and fatigue would be 
found in this study from a pathophysiological aspect. The dyspnea experienced by the 
participants in this present study may be a result of decreased pulmonary function. The decreased 
pulmonary function may be due to changes in the structures of the lung and impaired gas 
exchange, which is associated with the disease trajectory of COPD. The decrease in pulmonary 
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 function may lead to poor oxygenation of muscles needed for physical performance, which may 
impact the fatigue levels experienced by individuals with COPD. 
 There were no significant relationships between dyspnea and any of the dimensions of 
fatigue based on the available MRC Dyspnea Scale grades for 30 participants. This may be 
explained by the variability in time frame in which dyspnea was assessed, the use of the most 
recent scores available, and from not having the participants’ dyspnea and fatigue measured 
concurrently.   
 When the MRC Dyspnea Scale grades were grouped according to when the participants’ 
dyspnea were assessed (within the last three months, within the last 3 to 6 months, within the last 
6 to 12 months, and over 12 months ago) to determine if there were any significant relationships 
with fatigue, there were only significant negative relationships between the scores at the 3 to 6 
months interval and both the general fatigue (ρ = -0.92, p < 0.05) and physical fatigue (ρ = -0.92, 
p < 0.05) MFI subscales. No other significant relationships were found. The MRC Dyspnea 
Scale grades were grouped in this manner because the participants are assessed when they start 
pulmonary rehabilitation, as well as after 3, 6, and 12 months. Although the results showed that 
there was a significant relationship between dyspnea and fatigue, this finding is unfortunately not 
very helpful in terms of generalizability because the significance of this relationship was 
calculated based on five of the participants’ MRC Dyspnea Scale grades. However, when the 
MRC Dyspnea Scale grades were dichotomized into two groups (within the last six months and 
over six months ago) to increase the number of participants’ scores in each group, there were no 
significant relationships between dyspnea and fatigue. Findings from this present study 
contrasted with previous studies where a significant relationship between dyspnea and fatigue 
was found (Gift & Shepard, 1999; Janson-Bjerklie et al., 1986; Kapella et al., 2006; Kinsman et 
al., 1983; Reishtein, 2005; Woo, 2000a; Woo, 2000b). Furthermore, one study used the MFI and 
the results showed a significant relationship between dyspnea and all the MFI subscales (Oh et 
al., 2004). Oh et al. used a different instrument to measure dyspnea (Baseline Dyspnea Index), 
but dyspnea and fatigue were measured concurrently.  
 With a mean distance of 356 metres on the 6MWT, the participants in this present study 
had a higher activity tolerance than subjects in another study with mild COPD (Woo, 2000a), 
which included 22 subjects. The opposite was found in three studies where participants with 
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 severe COPD (Carter et al., 2003; Starobin et al., 2006), and mild COPD (Woo, 2000b) had a 
higher activity tolerance than the subjects in this present study. 
 There were no significant relationships between activity limitation and any of the 
dimensions of fatigue based on the 6MWT distances available for 41 participants. The lack of 
significant relationships between activity limitation and the fatigue dimensions may have been 
attributed to the various assessment time intervals at which the 6MWT was conducted among the 
participants, and the use of the most recent 6MWT distance available in this study. In addition, 
the 6MWT was conducted by various staff at the pulmonary rehabilitation program, which may 
have affected its reliability. 
 There have been inconsistent findings on the relationship between activity limitation and 
fatigue. There was a significant relationship between the 6MWT and fatigue in three COPD 
studies, indicating that activity limitation was related to fatigue (Breslin et al., 1998; Woo, 
2000a; Woo, 2000b). In another study which did not use the 6MWT but used the MFI, there 
were no significant relationships between any of the MFI subscales and measures of activity 
limitation (Breukink et al., 1998). Very few studies have examined the relationship between the 
6MWT and various dimensions of fatigue in individuals with COPD. One such study conducted 
by Breslin et al. (1998) found significant relationships between three of the MFI subscales and 
the 6MWT.  
 There were no significant relationships between heart rate or oxygen saturation and any 
of the dimensions of fatigue. Heart rate and oxygen saturation were included in this present study 
because the information was readily available, and to the researcher’s knowledge, these two 
variables have not been studied in the context of fatigue in COPD. Participants often recorded 
their readings after engaging in physical activity during their pulmonary rehabilitation session. It 
is important to note that the participants’ fatigue was measured at a time that was convenient for 
them during their pulmonary rehabilitation session. As a result, some of the participants’ fatigue 
was measured before they engaged in physical activity, and some was measured after physical 
activity. Since heart rate and oxygen saturation were not measured at the same time with fatigue, 
this may be a possible explanation for the lack of significant relationships.   
6.9 Psychologic Factors 
 On the HADS anxiety subscale, 42.9% of the participants scored an eight or higher, 
indicating a probable presence of clinical anxiety. Compared to anxiety, fewer participants 
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 scored an eight or higher on the HADS depression subscale, indicating a probable presence of 
clinical depression in 21.4% of the participants. It has been found that in individuals with COPD, 
there is a significant relationship between anxiety and an increased risk of re-hospitalization after 
an acute exacerbation (Gudmundsson et al., 2005). Several studies have found that pulmonary 
rehabilitation impacted anxiety and depression in individuals with COPD (Guell et al., 2006; 
Kayahan, Karapolat, Atyntoprak, Atasever, & Ozturk, 2006; Paz-Diaz, Montes de Oca, Lopez, & 
Celli, 2007; Withers, Rudkin, & White, 1999). In this sample, with nearly 43% of the 
participants having probable presence of clinical anxiety and a prevalence rate that was nearly 
twice as high as depression, it is even more imperative that they continue with pulmonary 
rehabilitation to not only reduce anxiety, but also decrease the risks of re-hospitalizations after an 
acute exacerbation of COPD (O’Donnell et al., 2008). The participants receive an educational 
component in addition to the monitored exercise component in the pulmonary rehabilitation 
program. One educational session is focused on coping with COPD. Participants receive 
education on suggested techniques to help them cope physically, mentally, socially, and 
spiritually, which potentially impacts the management of anxiety and depression. The pulmonary 
rehabilitation program is focused mainly on physical techniques such as stretching exercises, 
walking, and breathing techniques, which are incorporated in the exercise component of the 
program. However, the high levels of anxiety experienced by nearly half of the participants may 
suggest that incorporating additional techniques into the program such as mental, social and 
spiritual components, can be more effective in managing anxiety and depression. Higher levels 
of anxiety were also found in two other studies which used the HADS on subjects with severe 
COPD (Bestall et al., 1999; Dowson et al., 2001).   
 There was a significant negative relationship between anxiety and reduced motivation, 
but no significant relationships between depression and any of the MFI subscales. When 
participants experienced higher levels of anxiety, their scores suggested that they had greater 
motivation. Anxiety is an emotion, and emotions are felt experiences which form the basis of 
motivation (Ninan & Dunlop, 2006). Motivation is a readiness to react (Ninan & Dunlop), act in 
a purposeful manner…get past hurdles…and exists as energy, a wanting, drive, activity” 
(Sussman, Nezami, Pokhrel & Ames, 2007, p. 10). Often, individuals with COPD become 
anxious due to dyspnea (Grant & Moore, 2007), where fear may be associated with episodes of 
breathlessness which were experiences felt in the past. According to the self-regulation models 
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 of motivation, one is motivated to maintain system balance or an optimal state (Sussman, 
Nezami, Pokhrel & Ames). An awareness of a lack of system balance will motivate one to exert 
effort to restore balance. This model can be applied to this study which can explain this 
significant relationship. As the participants became increasingly anxious, perhaps due to the fear 
of dyspnea associated with activity, they became more motivated to restore emotional balance in 
the body. This may have led to a decrease in anxiety, a decrease in emotional distress, and a 
decrease in the amount of emotional fatigue experienced.  
 In two COPD studies which used the MFI and other instruments to measure anxiety and 
depression, significant positive relationships between all MFI subscales and mood, which 
included anxiety and depression, were noted by Oh et al. (2004); however, Breslin et al. (1998) 
found that the relationships were only significant between the general and mental fatigue 
subscales and depression. Other fatigue, anxiety and depression instruments were used in several 
other COPD studies where findings indicated that fatigue was significantly and positively related 
to negative mood (Small & Graydon, 1992), anxiety and depression (Kapella et al., 2006), and 
depression only (Gift & Shepard, 1999). In a cancer study, Smets et al. (1996) found a significant 
positive relationship between all MFI subscales and the HADS anxiety and depression subscales. 
The lack of a significant relationship between depression and fatigue in this present study may 
have been from the small sample size used. The sample size calculation was based on the MFI, 
and not the HADS; therefore, there may have been insufficient power to detect a significant 
relationship.   
6.10 Situational Factors 
 A mean of 7.1 on the PSQI indicated that most participants in this study experienced 
some sleep difficulties in the areas of sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleep medication, or daytime dysfunction. Higher PSQI 
scores indicate greater sleep difficulty or worse sleep quality; however, it does not differentiate 
the severity of sleep difficulty to help interpret the participants’ quality of sleep. In order to 
differentiate the quality of sleep to help make the findings in this present study more meaningful, 
the researcher decided that a score between 0 and 6 indicated mild sleep difficulty, a score 
between 7 and 13 indicated moderate sleep difficulty, and a score between 14 and 21 indicated 
severe sleep difficulty. Decisions on these score ranges were guided by the frequency 
distribution of the participants’ scores. In addition, these ranges were approximately equally 
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 divided into the three severity of sleep difficulty categories. According to these score ranges, 
52.3% of the participants experienced mild sleep difficulty, 38.1% experienced moderate sleep 
difficulty, and 9.6% indicated severe sleep difficulty. Participants in the present study had 
slightly better sleep quality than those in a study by Reishtein (2005) who had a mean of 8.69.  
 There were no significant relationships between sleep quality and any of the dimensions 
of fatigue. The lack of significant relationships may be attributed to the longer one-month 
assessment time interval of sleep disturbances when compared to the shorter assessment time 
intervals for the MFI and HADS, the longer one-month recall of sleep disturbances required in 
the PSQI, and the use of a small sample size. The sample size calculation was based on the MFI, 
and not the PSQI; therefore, there may have been insufficient power to detect a significant 
relationship. There have been conflicting findings on the relationship between sleep quality and 
fatigue. Significant relationships between sleep quality and fatigue were noted by Kapella et al. 
(2006) and Oh et al. (2004), but not in another study conducted by Reishtein (2005). While all 
these studies used the PSQI, a single item measuring sleep quality was used by Oh et al. The lack 
of a significant relationship between fatigue and sleep quality has also been found in other 
clinical populations. Lee et al. (1999) found that sleep disturbance was a poor predictor of 
fatigue in women with HIV.     
6.11 Other Findings 
 There were no significant differences among those who used supplemental oxygen and 
those who did not use supplemental oxygen; among ex-smokers, current smokers, and non-
smokers; and among the different MRC Dyspnea Scale grades on the four dimensions of 
subjective fatigue. In addition, the number of co-morbidities and the amount of pulmonary 
rehabilitation received were both not significantly related to any of the fatigue dimensions. In 
one study conducted on the general population, there was a significant relationship between 
certain co-morbidities and fatigue in the general population (Loge et al., 1998). Although data on 
the specific co-morbidities were not collected, perhaps some of co-morbidities which the 
participants had in this present study may not have affected the amount of fatigue they 
experienced. If more specific data on the participants’ co-morbidities were collected and 
categorized into various types, the significance of the relationship may have changed. The lack 
of a significant relationship between the amount of pulmonary rehabilitation received and fatigue 
was unexpected. This may have been due to some of the participants not attending pulmonary 
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 rehabilitation regularly, which had been brought up by the coordinator of the program. The 
irregular attendance suggests the need for a longitudinal assessment.  
6.12 Recommendations for Future Studies 
 Some recommendations for future studies include: examining other physiologic, 
psychologic and situational factors to determine their relationships with various dimensions of 
fatigue, recruiting more individuals from pulmonary rehabilitation programs since there has been 
limited research conducted with this particular group, examining whether pulmonary 
rehabilitation is effective in reducing fatigue levels, conducting longitudinal studies, conducting 
more validation studies for the use of the HADS in the COPD population, and including healthy 
older individuals for comparison studies. 
6.13 Implications for Nursing Practice 
 Fatigue is prevalent in the COPD population, and should be assessed, monitored, and 
managed by nurses. The MFI is a practical instrument to use for assessing fatigue in pulmonary 
rehabilitation, which can easily be incorporated into the preliminary assessment, and can later be 
assessed and monitored by incorporating it into the periodic assessments. However, a single-
dimensional instrument, such as a VAS may be more practical to use in a clinical setting to 
screen for the presence and severity of fatigue first, because it is quicker to complete than the 
MFI. The MFI could then be used to provide a more detailed assessment if needed. For research 
use, it would be more appropriate to use the MFI than single-dimensional instruments due to its 
comprehensiveness in assessing fatigue. Dyspnea is often assessed in individuals with COPD. 
Although fatigue is a very common and distressing symptom in individuals with COPD, it is 
poorly assessed and monitored in the clinical setting. Nurses and allied healthcare providers who 
work with clients with COPD not only in pulmonary rehabilitation, but also in the community 
and acute care settings could use both the VAS and MFI to assess for and monitor their clients’ 
fatigue. Until the complexity of fatigue in COPD is better understood through more research, and 
more effective fatigue management strategies can then be developed, nurses and allied healthcare 
providers in the clinical setting can help stress the importance of fatigue in COPD by assessing 
and monitoring it.   
6.14 Strengths 
 This present study was one of the few studies that have examined different dimensions of 
fatigue in the COPD and pulmonary rehabilitation populations. Other strengths of this study 
59 
 included: (a) the high participation rate, and (b) the use of a multidimensional fatigue instrument 
which is more comprehensive in assessing fatigue than single-dimensional instruments. 
6.15 Limitations 
 Some limitations of this present study included: (a) the uncontrolled extraneous variables, 
(b) the convenience sampling method, (c) not having a control group for comparison, (d) the 
possibility of social desirability bias, (e) the missing data, (f) the possibility of an inadequate 
sample size and insufficient statistical power for finding a significant relationship between 
anxiety, depression, and sleep quality for the four dimensions of fatigue, and (g) the increased 
possibility of making a type I error. The uncontrolled extraneous variables including: age, 
gender, co-morbidities, smoking status, supplemental oxygen use, and amount of pulmonary of 
rehabilitation received may affect internal validity. The non-probability convenience sampling 
method used does not assure that every individual with COPD in the COPD population has an 
equal chance of being included in the sample, which limits the generalizability of the findings. 
Therefore, one should be cautioned in generalizing the findings from this study to other 
individuals with COPD. Only individuals with COPD who attended pulmonary rehabilitation 
were included in the study. Others with COPD who are affected by the distressing effects of 
fatigue were excluded. Since self-report questionnaires were used in this study, participants may 
have responded in a manner that is favoured by society and not respond accurately to reflect their 
situation. The missing data on the MRC Dyspnea Scale grades may have affected the 
significance of the relationships between dyspnea and the different dimensions of fatigue. The 
missing data on pulmonary function tests affected the accurateness in the description of the 
participants’ characteristics. The sample size calculation was based on the MFI, and not on the 
HADS or PSQI. The sample size may have been too small for examining anxiety, depression, 
and sleep quality; therefore, there may have been insufficient statistical power to detect a 
significant relationship between these influencing factors and the four dimensions of fatigue. By 
running multiple separate comparison and correlational models for each variable, there is an 
increased possibility of making a type I error. 
6.16 Other Considerations 
 Complete and current data for all 42 participants for the MRC Dyspnea Scale and the 
PFTs would have been helpful. The data for the PFTs would have been helpful to describe the 
participant characteristics more accurately. If this study were to be repeated, assessing activity 
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 limitation, followed by measuring heart rate and oxygen saturation, dyspnea, and fatigue would 
be completed at one time by the researcher. Depression, anxiety, and sleep quality would then be 
measured by the researcher immediately or shortly afterwards at another time depending on the 
participants’ preference. Following this order of assessment can help reduce the variability in the 
assessment times, and increase the reliability of the 6MWT. More stringent data collection 
methods for assessing the participants’ attendance would be helpful in examining the amount of 
pulmonary rehabilitation received more accurately, and more specific data on the types of co-
morbidities would be collected. 
 The MFI and PSQI were appropriate instruments to use with this population because 
many participants found that they were easy and quick to complete. The MFI measured various 
dimensions of fatigue, and the PSQI measured various sleep disturbances in a short period of 
time and commitment on the participants’ part. The researcher found some difficulty interpreting 
the scores in both instruments because of the lack of specific guidelines to help understand the 
ranges of scores and its associated meaning. The MFI and PSQI may be more useful on a 
comparative basis to help measure changes over time for fatigue and sleep quality. The HADS 
has not been used extensively in the COPD population. More validation studies are needed to 
determine whether the HADS is an appropriate instrument to measure anxiety and depression in 
the COPD population. The conceptual framework used in this present study worked well in 
conceptualizing the relationships between the influencing factors and three of the four fatigue 
dimensions (emotional, behavioural, and cognitive). Guided by the results of the study, the 
general fatigue dimension should not be conceptualized together with the physical fatigue 
dimension. Therefore, the new conceptual framework would include five dimensions of 
subjective fatigue (emotional, behavioural, cognitive, physical, and general).  
6.17 Conclusion 
 Fatigue is a complex and multidimensional sensation which is common in individuals 
with COPD. Its distressing effects are reported to negatively affect these individuals’ functioning 
in terms of their quality of life. Fatigue in COPD has not been a well researched area when 
compared to other chronic illnesses such as cancer. However, from the research that has 
examined fatigue in COPD, most have focused on a single dimension: the intensity or severity of 
the fatigue experienced. Limited research has been conducted to examine the various dimensions 
of fatigue in the COPD population, and some factors that may be related to the fatigue 
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 experienced. The results of this feasibility study suggested that: (a) most of the participants (61.9 
- 81.0%) experienced moderate levels of subjective fatigue in all four dimensions (emotional, 
behavioural, cognitive, and physical), (b) moderate to severe levels of physical fatigue were 
experienced in 95.3% of the participants, (c) the only significant relationship was between 
anxiety and emotional fatigue; all other relationships were statistically insignificant, (d) there 
were no significant differences between sex, supplemental oxygen use, smoking status, and 
severity of dyspnea based on the MRC Dyspnea Scale grades on the four dimensions of 
subjective fatigue, and (e) many of the participants had probable presence of clinical anxiety 
(42.9%), where the prevalence of anxiety was nearly twice as high as depression (21.4%). The 
findings from this study will help healthcare professionals increase their understanding of fatigue 
in individuals with COPD who attend pulmonary rehabilitation, and work towards developing 
effective interventions in reducing the distressing effects of fatigue to help improve the quality of 
life in these individuals. 
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Appendix D: 
Consent Form for Participation in Research Study 
 
Unique Identification Number: _______ 
 
You are invited to participate in a research study called, Assessment of Fatigue in Patients with 
Chronic Obstructive Pulmonary Disease (COPD) Participating in a Pulmonary Rehabilitation 
Program: A Feasibility Study. Please read this form carefully, and feel free to ask questions you 
might have.  
 
Researcher:  Cindy Wong, B.S.N., R.N.; College of Nursing, University of Saskatchewan. 
Phone number: (306) 262-6882; E-mail: cjw920@mail.usask.ca 
 
Purpose and Procedure:  The purpose of this study is to find out how some factors may be 
affecting fatigue in people with COPD. The main factors that will be studied are: fatigue, 
shortness of breath, how far a person with COPD can walk in the 6-minute walk test, depression, 
anxiety, sleep quality, how fast the heart beats in a person with COPD, and the amount of oxygen 
in the blood of a person with COPD. How these factors relate to fatigue will also be studied. 
 
I will be giving you four forms to fill out which has questions on them. The first three forms will 
take about 5-10 minutes each to complete. The forms are about fatigue, depression and anxiety, 
and sleep quality. The last form is very short and collects information about your age and gender. 
Collecting this information will help me understand more about the individuals in this study. I 
will be guiding you through these questions to make sure that you understand them, and answer 
any questions you may have. In each form, I will be reading the questions out loud and 
displaying the question on a sheet of paper in large writing. We will continue this process until 
all the forms are complete.  
 
Some information will be obtained from your health record (with your consent). This information 
includes: your lung function tests, the distance you walked in your 6-minute walk test, how short 
of breath you get when you are doing physical activity, how fast your heart beats, the amount of 
oxygen in your blood, the medications you are taking, your smoking status, the amount of 
pulmonary rehabilitation you have received, other medical conditions you may have, and if you 
use an oxygen tank. Collecting this important information from your health record will help me 
study whether these factors can affect fatigue in people with COPD. The information collected in 
this study will be reported in a group format for a thesis, possible publications (such as research 
articles), and possible presentations at conferences. 
□  I give consent for the researcher to access my health record. 
□  I do not give consent for the researcher to access my health record. 
 
After the study is finished, you may receive the study’s results. This can be done by writing your 
mailing address on a form I can give you.  
 
Possible benefits: Participating in this study can help people involved in healthcare better 
understand the complex nature of fatigue, and what factors maybe affecting fatigue in people 
who have COPD. This study can eventually help reduce fatigue in people who have COPD. But, 
these benefits are not necessarily guaranteed. 
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Unique Identification Number: _______ 
 
Potential Risk: One possible discomfort to participating in this study is feeling fatigued or tired 
from completing the questionnaires. Please take your time in completing these questionnaires, 
but if you are feeling tired, please let me know and you are more than welcome to take breaks. 
 
Storage of Data: All information will be stored in secured locations at the College of Nursing, 
University of Saskatchewan for five years. When the information is no longer required, it will be 
appropriately destroyed. Only the research team will be able to look at the information. 
 
Confidentiality: Your name will not appear on any of the questionnaires or the demographic 
form. Please do not put your name or any other identification on any of these questionnaires 
or the demographic form. Instead, only a unique identification number will be used on the 
questionnaires and demographic form to help me keep track of the completed questionnaires and 
demographic form. I will be the only person who is aware of your identity. The master list of all 
the participants’ names and unique identification numbers, the form you fill out if you would like 
to receive the study results, and the consent form will be stored separately from the rest of the 
data collected so that it will not be possible to associate a name with any information.  
 
Right to Withdraw: Your participation will help to better understand the complex nature of 
fatigue, and what factors maybe affecting fatigue in people who have COPD. But, your 
participation is entirely your choice, and you can answer only those questions that you are 
comfortable with. There is no guarantee that you will personally benefit from your involvement, 
but you may be more aware of the amount of fatigue you experience. The information you share 
will be held in strict confidence and discussed only with the research team. You may withdraw 
your participation in the study for any reason, at any time, without penalty of any sort. 
Withdrawing your participation in the study will not affect your medical care or access to health 
care services. Should you choose to withdraw your participation in the study, the information you 
shared will be deleted from the research project and destroyed, at your request. 
 
Questions: If you have any questions concerning the research project, please feel free to ask at 
any point. You are also free to contact me by phone or e-mail, as provided above if you have 
other questions. You may also contact the researcher supervisor, Dr. Donna Goodridge by phone 
at (306) 966-1478 or e-mail at donna.goodridge@usask.ca. This study has been approved on 
ethical grounds by the University of Saskatchewan Behavioural Research Ethics Board on 
October 9th, 2008, and by the Saskatoon Health Region on October 17th, 2008. If you have any 
questions about your rights as a participant, please contact the Ethics Office at (306) 966-2084. 
Out of town participants may call collect. 
 
Consent to Participate: I have read and understood the description provided above. I have been 
provided with an opportunity to ask questions and my questions have been answered. I consent to 
participate in the research project, understanding that I may withdraw my consent at any time. A 
copy of this Consent Form has been given to me for my records. 
 
___________________     ____________  ____________________     ____________  
Signature of Participant     Date   Signature of Researcher      Date 
 
 Appendix E: Demographic Form 
 
Date: _____________            Unique Identification Number: _______ 
 
Instructions: This form is designed to help the researcher understand more about 
the individuals in this study. Please answer each question by placing an X in the 
most appropriate box or filling in the blank. Please do no put your name, or any 
other identification on this form. 
 
 
Age: ________ (in years) 
 
 
Sex: □ Male       □ Female 
 
 
 
 
Thank you for taking the time to complete this form.
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 Appendix F: Chart Abstraction Sheet 
 
Date: _____________            Unique Identification Number: _______ 
 
1) Activity Limitation – 6MWT 
 
Most recent assessment time interval: □ preliminary  □ 3 months 
□ 6 months  □ 12 months 
 
Distance walked in 6 minutes: _______ metres 
 
2) Dyspnea - MRC Dyspnea Scale 
 
Most recent assessment time interval: □ preliminary  □ 3 months 
□ 6 months  □ 12 months 
 
Grade Description 
1 Not troubled with breathlessness except with strenuous exercise. 
2 Troubled by shortness of breath when hurrying on the level or walking up a 
slight hill. 
3 Walks slower than people of the same age on the level because of 
breathlessness or has to stop because of breathlessness when walking at 
own pace on the level. 
4 Stops for breath after walking about 100 yards (90 metres) or after a few 
minutes on the level. 
5 Too breathless to leave the house or breathless when dressing or 
undressing. 
 
3) Smoking Status (during preliminary assessment) 
□ Non-smoker □ Currently smoking  □ Ex-smoker  
 
4) Amount of Pulmonary Rehabilitation Received 
 
 Date of first day participant began attending pulmonary rehabilitation: 
 _____ / _____ / _____ 
   Day Month    Year 
 
5) Co-morbidities (during preliminary assessment period) 
 
 Number of co-morbidities: _______ 
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 Unique Identification Number: _______ 
 
6) Supplemental Oxygen Use (during preliminary assessment) 
□ Uses supplemental oxygen 
□ Does not use supplemental oxygen 
 
7) Most Current Medications 
 
Medication Dose Medication Dose 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
8) Pulmonary Function Tests 
 
 Date of PFT: _____ / _____ / _____ 
              Day    Month  Year 
 
 FEV1: ______ 
  
FEV1 / FVC: ______ 
 
9) Oxygen Saturation and Heart Rate 
 
 Date: _____ / _____ / _____ 
  Day    Month  Year 
 
 O2 sat: _____ % HR: _____ beats / minute 
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 Appendix G: Request for Results From the Research Study 
 
I would like to receive a copy of the results from the research study called, Assessment of 
Fatigue in Patients with Chronic Obstructive Pulmonary Disease (COPD) Participating in a 
Pulmonary Rehabilitation: A Feasibility Study. 
 
Name:  
 
Mailing Address:  
 
City:  
 
Province:  
 
Postal Code: 
82 
 Appendix H: 
Master List of Participants and Associating Unique Identification Numbers 
 
Name of Participant Unique Identification Number 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
83 
  
Appendix I: Permission to Use MFI E-mail 
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Appendix J: Permission to Use PSQI E-mail 
 Appendix K: MFI 
 
  Date: _____________           Unique Identification Number: _______ 
 
MFI® MULTIDIMENSIONAL FATIGUE INVENTORY 
® E. Smets, B.Garssen, B. Bonke. 
 
 
 
Instructions: 
 
By means of the following statements we would like to get an idea of how you have been feeling lately. 
There is, for example, the statement: 
 "I FEEL RELAXED" 
If you think that this is entirely true, that indeed you have been feeling relaxed lately, please, place an X in the extreme 
left box; like this: 
 yes, that is true  ⌧1 2 3 4 5 no, that is not true 
 
The more you disagree with the statement, the more you can place an X in the direction of "no, that is not true". Please do 
not miss out a statement and place only one X in a box for each statement.  
 
1 I feel fit. yes, that is true 1 2 3 4 5 no, that is not true 
2 Physically, I feel only able to do a little. yes, that is true 1 2 3 4 5 no, that is not true 
3 I feel very active. yes, that is true 1 2 3 4 5 no, that is not true 
4 I feel like doing all sorts of nice things. yes, that is true 1 2 3 4 5 no, that is not true 
5 I feel tired. yes, that is true 1 2 3 4 5 no, that is not true 
6 I think I do a lot in a day. yes, that is true 1 2 3 4 5 no, that is not true 
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7 When I am doing something, I can  
keep my thoughts on it. 
yes, that is true 1 2 3 4 5 no, that is not true 
8 Physically I can take on a lot. yes, that is true 1 2 3 4 5 no, that is not true 
9 I dread having to do things. yes, that is true 1 2 3 4 5 no, that is not true 
10 I think I do very little in a day. yes, that is true 1 2 3 4 5 no, that is not true 
11 I can concentrate well. yes, that is true 1 2 3 4 5 no, that is not true 
12 I am rested. yes, that is true 1 2 3 4 5 no, that is not true 
13 It takes a lot of effort to concentrate  
on things. 
yes, that is true 1 2 3 4 5 no, that is not true 
14 Physically I feel I am in a bad condition. yes, that is true 1 2 3 4 5 no, that is not true 
15 I have a lot of plans. yes, that is true 1 2 3 4 5 no, that is not true 
16 I tire easily. yes, that is true 1 2 3 4 5 no, that is not true 
17 I get little done. yes, that is true 1 2 3 4 5 no, that is not true 
18 I don't feel like doing anything. yes, that is true 1 2 3 4 5 no, that is not true 
19 My thoughts easily wander. yes, that is true 1 2 3 4 5 no, that is not true 
20 Physically I feel I am in an excellent 
condition. 
yes, that is true 1 2 3 4 5 no, that is not true 
Smets, E. M. A., Garssen, B., Bonke, B., & de Haes, J. C. J. M. (1995). The Multidimensional Fatigue Inventory (MFI); psychometric qualities of an instrument to assess fatigue. Journal of 
 Psychomatic Research, 39(5), 315-325. 
               Unique Identification Number: _______ 
* A copy of this instrument was produced for the purpose of the thesis. Additional copies and use of this instrument would need to be sought or purchased appropriately. 
Thank you very much for your cooperation 
Permission to use the MFI was given by Dr. Smets 
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 Appendix L: HADS 
(* Copy shown, originals were purchased from GL Assessment) 
Date: ______________           Unique Identification Number: _______ 
 
*A copy of this instrument was produced for the purpose of the thesis. Additional copies and use of this instrument would need  
to be sought or purchased appropriately. 
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 Appendix M: PSQI 
 
Date: _____________            Unique Identification Number: _______ 
 
PITTSBURGH SLEEP QUALITY INDEX 
 
INSTRUCTIONS: 
The following questions relate to your usual sleep habits during the past 
month only. Your answers should indicate the most accurate reply for the 
majority of days and nights in the past month. 
Please answer all questions. 
 
1.  During the past month, what time have you usually gone to bed at 
night? 
BED TIME ___________ 
 
2.  During the past month, how long (in minutes) has it usually taken you 
to fall asleep each night? 
 
NUMBER OF MINUTES ___________ 
 
3.  During the past month, what time have you usually gotten up in the 
morning? 
 
GETTING UP TIME ___________ 
 
4.  During the past month, how many hours of actual sleep did you get at 
night? (This may be different than the number of hours you spent in 
bed.) 
 
HOURS OF SLEEP PER NIGHT ___________ 
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For each of the remaining questions, check the one best response. Please answer 
all questions. 
 
5.  During the past month, how often have you had trouble sleeping 
because you . . . 
 
a)  Cannot get to sleep within 30 minutes 
 
Not during the       Less than                 Once or twice   Three or more 
past month_____  once a week_____  a week_____    times a week_____ 
 
b)  Wake up in the middle of the night or early morning 
 
Not during the       Less than                 Once or twice   Three or more 
past month_____  once a week_____   a week_____   times a week_____ 
 
c)  Have to get up to use the bathroom 
 
Not during the       Less than                 Once or twice   Three or more 
past month_____  once a week_____  a week_____    times a week_____ 
 
d)  Cannot breathe comfortably 
 
Not during the       Less than                 Once or twice   Three or more 
past month_____  once a week_____  a week_____    times a week_____ 
 
e)  Cough or snore loudly 
 
Not during the       Less than                 Once or twice   Three or more 
past month_____  once a week_____  a week_____    times a week_____ 
 
f)  Feel too cold 
 
Not during the       Less than                 Once or twice   Three or more 
past month_____  once a week_____  a week_____    times a week_____ 
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g)  Feel too hot 
 
Not during the       Less than                 Once or twice   Three or more 
past month_____  once a week_____  a week_____    times a week_____ 
 
h)  Had bad dreams 
 
Not during the       Less than                 Once or twice    Three or more 
past month_____  once a week_____  a week_____     times a week_____ 
 
i)  Have pain 
 
Not during the       Less than                 Once or twice    Three or more 
past month_____  once a week_____  a week_____     times a week_____ 
 
j)  Other reason(s), please describe ____________________________ 
___________________________________________________________ 
 
How often during the past month have you had trouble sleeping 
because of this? 
 
Not during the      Less than                  Once or twice    Three or more 
past month_____ once a week_____   a week_____     times a week_____ 
 
6.  During the past month, how would you rate your sleep quality overall? 
 
Very good ____________ 
Fairly good ____________ 
Fairly bad ____________ 
Very bad ____________ 
7.  During the past month, how often have you taken medicine to help 
you sleep (prescribed or "over the counter")? 
 
Not during the       Less than                 Once or twice    Three or more 
past month_____  once a week_____  a week_____     times a week_____ 
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8.  During the past month, how often have you had trouble staying 
awake while driving, eating meals, or engaging in social activity? 
 
Not during the       Less than                 Once or twice    Three or more 
past month_____  once a week_____  a week_____     times a week_____ 
 
9.  During the past month, how much of a problem has it been for you to 
keep up enough enthusiasm to get things done? 
 
No problem at all __________ 
Only a very slight problem __________ 
Somewhat of a problem __________ 
A very big problem __________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*A copy of this instrument was produced for the purpose of the thesis. Additional copies and use of this instrument would need  
to be sought or purchased appropriately. 
 
Permission to use the PSQI was given by Dr. Buysse 
 
 
Buysse, D. J., Reynolds, C. F., III, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A
 new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193-213 
 
